Cyclic	O
AMP	O
-responsive	B-DNA
element	I-DNA
-dependent	O
activation	O
of	O
Epstein-Barr	O
virus	O
zebra	B-DNA
promoter	I-DNA
by	O
human	O
herpesvirus	O
6	O
.	O

We	O
have	O
recently	O
shown	O
that	O
infection	O
of	O
Epstein-Barr	B-cell_line
virus	I-cell_line
(	I-cell_line
EBV	I-cell_line
)	I-cell_line
genome-positive	I-cell_line
B	I-cell_line
cells	I-cell_line
by	O
human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
results	O
in	O
the	O
expression	O
of	O
the	O
immediate-early	B-DNA
EBV	I-DNA
Zebra	I-DNA
gene	I-DNA
,	O
followed	O
by	O
virus	O
replication	O
(	O
L.Flamand	O
,	O
I.Stefanescu	O
,	O
D.V.Ablashi	O
,	O
and	O
J.Menezes	O
,	O
J.Virol.67	O
:	O
6768-6777	O
,	O
1993	O
)	O
.	O

Here	O
we	O
show	O
that	O
HHV-6	O
upregulates	O
Zebra	B-DNA
gene	I-DNA
transcription	O
through	O
a	O
cyclic	B-DNA
AMP-responsive	I-DNA
element	I-DNA
(	O
CRE	B-DNA
)	O
located	O
within	O
the	O
Zebra	B-DNA
promoter	I-DNA
(	O
Zp	B-DNA
)	O
.	O

Using	O
human	B-cell_line
B-	I-cell_line
or	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
transfected	O
with	O
ZpCat	B-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
,	O
we	O
demonstrate	O
that	O
a	O
region	O
designated	O
the	O
ZII	B-DNA
domain	I-DNA
of	O
Zp	B-DNA
is	O
the	O
target	O
of	O
HHV-6	O
transactivation	O
.	O

Mutation	O
of	O
the	O
consensus	B-DNA
AP-1/CRE	I-DNA
site	I-DNA
within	O
ZII	B-DNA
abolished	O
the	O
inducibility	O
of	O
Zp	B-DNA
by	O
HHV-6	O
,	O
whereas	O
positioning	O
of	O
the	O
ZII	B-DNA
domain	I-DNA
upstream	O
of	O
the	O
beta-globin	B-DNA
minimal	I-DNA
promoter	I-DNA
conferred	O
responsiveness	O
following	O
HHV-6	O
infection	O
.	O

Binding	O
of	O
these	O
factors	O
to	O
ZII	B-DNA
was	O
prevented	O
by	O
oligonucleotides	O
containing	O
CRE	B-DNA
but	O
not	O
by	O
AP-1	B-DNA
consensus	I-DNA
sequences	I-DNA
.	O

Antibodies	O
against	O
CRE-binding	B-protein
(	I-protein
CREB	I-protein
)	I-protein
protein	I-protein
but	O
not	O
against	O
c-Fos	B-protein
or	O
c-Jun	B-protein
were	O
able	O
to	O
supershift	O
the	O
DNA-protein	B-protein
complex	I-protein
,	O
identifying	O
the	O
nature	O
of	O
the	O
transcription	B-protein
factor	I-protein
which	O
binds	O
to	O
ZII	B-DNA
as	O
a	O
member	O
of	O
the	O
CREB	B-protein
family	I-protein
of	I-protein
proteins	I-protein
.	O

Finally	O
,	O
transfection	O
of	O
CREB	B-protein
protein	I-protein
and	O
protein	B-DNA
kinase	I-DNA
A	I-DNA
expression	I-DNA
vectors	I-DNA
were	O
found	O
to	O
activate	O
Zp	B-DNA
in	O
Jurkat	B-cell_type
cells	I-cell_type
,	O
suggesting	O
that	O
phosphorylated	O
form	O
of	O
CREB	B-protein
protein	I-protein
can	O
play	O
a	O
determining	O
role	O
in	O
the	O
EBV	O
reactivation	O
process	O
.	O

JournaL	NULL
or	NULL
ViRoLOoGY	NULL
,	NULL
Mar	NULL
.	NULL

1996	NULL
,	NULL
p.	NULL
1784-1791	NULL
0022-538	NULL
X	NULL
,	NULL
/96/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
©	NULL
1996	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

70	NULL
,	NULL
No	NULL
.	NULL

3	NULL
Cyclic	NULL
AMP-Responsive	NULL
Element-Dependent	NULL
Activation	NULL
of	NULL
Epstein-Barr	NULL
Virus	NULL
Zebra	NULL
Promoter	NULL
by	NULL
Human	NULL
Herpesvirus	NULL
6	NULL
LOUIS	NULL
FLAMANDt	NULL
anp	NULL
JOSE	NULL
MENEZES*	NULL
Laboratory	NULL
of	NULL
Immunovirology	NULL
,	NULL
Pediatric	NULL
Research	NULL
Centre	NULL
,	NULL
and	NULL
Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Immunology	NULL
,	NULL
University	NULL
of	NULL
Montreal	NULL
,	NULL
Montreal	NULL
,	NULL
Quebec	NULL
,	NULL
Canada	NULL
H3T	NULL
1C5	NULL
Received	NULL
29	NULL
September	NULL
1995/Accepted	NULL
5	NULL
December	NULL
1995	NULL
We	NULL
have	NULL
recently	NULL
shown	NULL
that	NULL
infection	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
genome-positive	NULL
B	NULL
cells	NULL
by	NULL
human	NULL
herpesvirus	NULL
6	NULL
(	NULL
HHV-6	NULL
)	NULL
results	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
immediate-early	NULL
EBV	NULL
Zebra	NULL
gene	NULL
,	NULL
followed	NULL
by	NULL
virus	NULL
replication	NULL
(	NULL
L.	NULL
Flamand	NULL
,	NULL
I.	NULL
Stefanescu	NULL
,	NULL
D.	NULL
V.	NULL
Ablashi	NULL
,	NULL
and	NULL
J.	NULL
Menezes	NULL
,	NULL
J.	NULL
Virol	NULL
.	NULL

67:6768-6777	NULL
,	NULL
1993	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
HHV-6	NULL
upregulates	NULL
Zebra	NULL
gene	NULL
transcription	NULL
through	NULL
a	NULL
cyclic	NULL
AMP-responsive	NULL
element	NULL
(	NULL
CRE	NULL
)	NULL
located	NULL
within	NULL
the	NULL
Zebra	NULL
promoter	NULL
(	NULL
Zp	NULL
)	NULL
.	NULL

Using	NULL
human	NULL
B-	NULL
or	NULL
T-cell	NULL
lines	NULL
transfected	NULL
with	NULL
ZpCat	NULL
reporter	NULL
gene	NULL
constructs	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
a	NULL
region	NULL
designated	NULL
the	NULL
ZII	NULL
domain	NULL
of	NULL
Zp	NULL
is	NULL
the	NULL
target	NULL
of	NULL
HHV-6	NULL
transactivation	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
consensus	NULL
AP-1/CRE	NULL
site	NULL
within	NULL
ZII	NULL
abolished	NULL
the	NULL
inducibility	NULL
of	NULL
Zp	NULL
by	NULL
HHV-6	NULL
,	NULL
whereas	NULL
positioning	NULL
of	NULL
the	NULL
ZII	NULL
domain	NULL
upstream	NULL
of	NULL
the	NULL
§-globin	NULL
minimal	NULL
promoter	NULL
conferred	NULL
responsiveness	NULL
following	NULL
HHV-6	NULL
infection	NULL
.	NULL

Binding	NULL
of	NULL
transcription	NULL
factors	NULL
to	NULL
ZII	NULL
were	NULL
not	NULL
induced	NULL
by	NULL
HHV-6	NULL
or	NULL
tetradecanoyl	NULL
phorbol	NULL
acetate	NULL
treatment	NULL
.	NULL

Binding	NULL
of	NULL
these	NULL
factors	NULL
to	NULL
ZII	NULL
was	NULL
prevented	NULL
by	NULL
oligonucleotides	NULL
containing	NULL
CRE	NULL
but	NULL
not	NULL
by	NULL
AP-1	NULL
consensus	NULL
sequences	NULL
.	NULL

Antibodies	NULL
against	NULL
CRE-binding	NULL
(	NULL
CREB	NULL
)	NULL
protein	NULL
but	NULL
not	NULL
against	NULL
c-Fos	NULL
or	NULL
c-Jun	NULL
were	NULL
able	NULL
to	NULL
supershift	NULL
the	NULL
DNA-protein	NULL
complex	NULL
,	NULL
identifying	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
which	NULL
binds	NULL
to	NULL
ZII	NULL
as	NULL
a	NULL
member	NULL
of	NULL
the	NULL
CREB	NULL
family	NULL
of	NULL
proteins	NULL
.	NULL

Finally	NULL
,	NULL
transfection	NULL
of	NULL
CREB	NULL
protein	NULL
and	NULL
protein	NULL
kinase	NULL
A	NULL
expression	NULL
vectors	NULL
were	NULL
found	NULL
to	NULL
activate	NULL
Zp	NULL
in	NULL
Jurkat	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
phosphorylated	NULL
form	NULL
of	NULL
CREB	NULL
protein	NULL
can	NULL
play	NULL
a	NULL
determining	NULL
role	NULL
in	NULL
the	NULL
EBV	NULL
reactivation	NULL
process	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
and	NULL
human	NULL
herpesvirus	NULL
6	NULL
(	NULL
HHV-6	NULL
)	NULL
are	NULL
pathogenic	NULL
herpesviruses	NULL
that	NULL
are	NULL
distributed	NULL
worldwide	NULL
.	NULL

EBV	NULL
infection	NULL
of	NULL
human	NULL
B	NULL
lymphocytes	NULL
results	NULL
in	NULL
the	NULL
immor-talization	NULL
of	NULL
these	NULL
cells	NULL
,	NULL
with	NULL
the	NULL
virus	NULL
remaining	NULL
in	NULL
a	NULL
latent	NULL
state	NULL
,	NULL
expressing	NULL
a	NULL
minimum	NULL
of	NULL
six	NULL
nuclear	NULL
proteins	NULL
(	NULL
EBNAs	NULL
1	NULL
,	NULL
2	NULL
,	NULL
3A	NULL
,	NULL
3B	NULL
,	NULL
and	NULL
3C	NULL
and	NULL
EBNA	NULL
LP	NULL
)	NULL
and	NULL
three	NULL
membrane	NULL
polypeptides	NULL
(	NULL
LMP1	NULL
,	NULL
LMP2A	NULL
,	NULL
and	NULL
LMP2B	NULL
)	NULL
(	NULL
for	NULL
a	NULL
review	NULL
,	NULL
see	NULL
reference	NULL
12	NULL
)	NULL
.	NULL

EBV	NULL
latency	NULL
can	NULL
be	NULL
disrupted	NULL
by	NULL
the	NULL
unique	NULL
presence	NULL
of	NULL
the	NULL
38-kDa	NULL
immediate-early	NULL
nucleophosphopro-tein	NULL
Zebra	NULL
(	NULL
6	NULL
,	NULL
11	NULL
,	NULL
51	NULL
)	NULL
.	NULL

Zebra	NULL
has	NULL
amino	NULL
acid	NULL
regions	NULL
partially	NULL
homologous	NULL
to	NULL
those	NULL
found	NULL
in	NULL
the	NULL
product	NULL
of	NULL
the	NULL
cellular	NULL
proto-oncogene	NULL
c-fos	NULL
and	NULL
can	NULL
transactivate	NULL
various	NULL
EBV	NULL
promoters	NULL
through	NULL
DNA	NULL
binding	NULL
of	NULL
AP-1	NULL
and	NULL
cyclic	NULL
AMP-responsive	NULL
element	NULL
(	NULL
CRE	NULL
)	NULL
consensus	NULL
sequences	NULL
(	NULL
5	NULL
,	NULL
35	NULL
,	NULL
36	NULL
)	NULL
.	NULL

The	NULL
Zebra	NULL
gene	NULL
(	NULL
also	NULL
referred	NULL
to	NULL
as	NULL
the	NULL
BZLF1	NULL
gene	NULL
)	NULL
is	NULL
under	NULL
the	NULL
control	NULL
of	NULL
a	NULL
promoter	NULL
(	NULL
Zp	NULL
)	NULL
containing	NULL
elements	NULL
responsive	NULL
to	NULL
phorbol	NULL
esters	NULL
and	NULL
anti-immunoglobulin	NULL
G	NULL
(	NULL
IgG	NULL
)	NULL
(	NULL
17	NULL
,	NULL
49	NULL
)	NULL
.	NULL

Maximal	NULL
transcription	NULL
from	NULL
this	NULL
promoter	NULL
is	NULL
rapidly	NULL
observed	NULL
,	NULL
within	NULL
2	NULL
h	NULL
,	NULL
and	NULL
occurs	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
protein	NULL
inhibitors	NULL
such	NULL
as	NULL
cycloheximide	NULL
and	NULL
anisomycin	NULL
,	NULL
although	NULL
much	NULL
less	NULL
effi-ciently	NULL
.	NULL

Furthermore	NULL
,	NULL
Flemington	NULL
and	NULL
Speck	NULL
(	NULL
19	NULL
)	NULL
have	NULL
described	NULL
an	NULL
autoregulatory	NULL
mechanism	NULL
of	NULL
Zebra	NULL
expression	NULL
.	NULL

First	NULL
,	NULL
an	NULL
external	NULL
stimulus	NULL
such	NULL
as	NULL
tetradecanoyl	NULL
phorbol	NULL
acetate	NULL
(	NULL
TPA	NULL
)	NULL
leads	NULL
to	NULL
low-level	NULL
transcription	NULL
of	NULL
the	NULL
BZLF1	NULL
gene	NULL
.	NULL

The	NULL
translated	NULL
product	NULL
Zebra	NULL
binds	NULL
to	NULL
a	NULL
region	NULL
within	NULL
Zp	NULL
(	NULL
domains	NULL
ZIIIA	NULL
and	NULL
ZIIIB	NULL
)	NULL
located	NULL
between	NULL
-134	NULL
and	NULL
-104	NULL
from	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
and	NULL
transactivates	NULL
its	NULL
own	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Pediatric	NULL
Research	NULL
Cen-ter	NULL
,	NULL
Ste-Justine	NULL
Hospital	NULL
,	NULL
3175	NULL
Cote	NULL
Ste-Catherine	NULL
Rd	NULL
.	NULL

,	NULL
Montreal	NULL
,	NULL
Quebec	NULL
,	NULL
Canada	NULL
H3T	NULL
1C5	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
514	NULL
)	NULL
345-4728	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
514	NULL
)	NULL
345-4801	NULL
.	NULL

¢	NULL
Present	NULL
address	NULL
:	NULL
Laboratory	NULL
of	NULL
Tumor	NULL
Cell	NULL
Biology	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
20892	NULL
.	NULL

1784	NULL
promoter	NULL
,	NULL
leading	NULL
to	NULL
high	NULL
levels	NULL
of	NULL
Zebra	NULL
mRNA	NULL
and	NULL
protein	NULL
.	NULL

Zebra	NULL
can	NULL
transactivate	NULL
various	NULL
other	NULL
promoters	NULL
and	NULL
is	NULL
responsible	NULL
for	NULL
initiating	NULL
the	NULL
cascade	NULL
of	NULL
events	NULL
leading	NULL
to	NULL
the	NULL
complete	NULL
EBV	NULL
replicative	NULL
cycle	NULL
.	NULL

HHV-6	NULL
has	NULL
the	NULL
ability	NULL
to	NULL
infect	NULL
various	NULL
cell	NULL
types	NULL
,	NULL
most	NULL
of	NULL
which	NULL
are	NULL
constituents	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
(	NULL
1	NULL
,	NULL
38	NULL
)	NULL
.	NULL

Upon	NULL
infection	NULL
of	NULL
T	NULL
lymphocytes	NULL
,	NULL
HHV-6	NULL
can	NULL
also	NULL
interact	NULL
with	NULL
other	NULL
viruses	NULL
,	NULL
such	NULL
as	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
,	NULL
and	NULL
transactivate	NULL
heterologous	NULL
viral	NULL
promoters	NULL
(	NULL
15	NULL
,	NULL
27	NULL
)	NULL
.	NULL

In	NULL
a	NULL
previous	NULL
study	NULL
(	NULL
16	NULL
)	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
infection	NULL
of	NULL
EBV	NULL
genome-positive	NULL
human	NULL
B	NULL
cells	NULL
by	NULL
HHV-6	NULL
results	NULL
in	NULL
activation	NULL
of	NULL
the	NULL
full	NULL
EBV	NULL
replicative	NULL
cycle	NULL
.	NULL

The	NULL
present	NULL
study	NULL
was	NULL
aimed	NULL
at	NULL
defining	NULL
the	NULL
molecular	NULL
mechanisms	NULL
by	NULL
which	NULL
EBV	NULL
is	NULL
reactivated	NULL
following	NULL
superinfection	NULL
by	NULL
HHV-6	NULL
.	NULL

Since	NULL
Zebra	NULL
activation	NULL
is	NULL
a	NULL
key	NULL
step	NULL
for	NULL
the	NULL
switch	NULL
from	NULL
latency	NULL
to	NULL
the	NULL
lytic	NULL
cycle	NULL
,	NULL
we	NULL
have	NULL
focused	NULL
our	NULL
study	NULL
on	NULL
Zebra	NULL
activation	NULL
by	NULL
HHV-6	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
Zp	NULL
is	NULL
strongly	NULL
activated	NULL
following	NULL
infection	NULL
of	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
with	NULL
HHV-6	NULL
.	NULL

The	NULL
element	NULL
responsive	NULL
to	NULL
HHV-6	NULL
infection	NULL
was	NULL
targeted	NULL
within	NULL
the	NULL
ZII	NULL
domain	NULL
of	NULL
Zp	NULL
,	NULL
a	NULL
region	NULL
containing	NULL
AP-1/cyclic	NULL
AMP	NULL
-responsive	NULL
element	NULL
(	NULL
CRE	NULL
)	NULL
consensus	NULL
sequence	NULL
,	NULL
to	NULL
which	NULL
binding	NULL
of	NULL
CRE-binding	NULL
(	NULL
CREB	NULL
)	NULL
or	NULL
CREB-like	NULL
proteins	NULL
is	NULL
observed	NULL
,	NULL
leading	NULL
to	NULL
Zp	NULL
activation	NULL
.	NULL

(	NULL
These	NULL
results	NULL
were	NULL
presented	NULL
in	NULL
part	NULL
at	NULL
the	NULL
first	NULL
International	NULL
Conference	NULL
on	NULL
Human	NULL
Herpesviruses	NULL
6	NULL
and	NULL
7	NULL
,	NULL
Abstr	NULL
.	NULL

12	NULL
,	NULL
held	NULL
in	NULL
Atlanta	NULL
,	NULL
Ga.	NULL
April	NULL
7-10	NULL
,	NULL
1995	NULL
.	NULL
)	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
lines	NULL
and	NULL
culture	NULL
conditions	NULL
.	NULL

The	NULL
cell	NULL
lines	NULL
Raji	NULL
,	NULL
HSB-2	NULL
,	NULL
and	NULL
Jurkat	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
,	NULL
Rockville	NULL
,	NULL
Md	NULL
.	NULL

Raji	NULL
is	NULL
an	NULL
EBV	NULL
genome-positive	NULL
human	NULL
B-cell	NULL
linc	NULL
,	NULL
HSB-2	NULL
is	NULL
an	NULL
immature	NULL
human	NULL
T-cell	NULL
line	NULL
,	NULL
and	NULL
Jurkat	NULL
has	NULL
a	NULL
fully	NULL
mature	NULL
T-lymphocyte	NULL
phenotype	NULL
.	NULL

All	NULL
cell	NULL
lines	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
50	NULL
U	NULL
of	NULL
penicillin	NULL
per	NULL
ml	NULL
,	NULL
50	NULL
mg	NULL
of	NULL
streptomycin	NULL
per	NULL
ml	NULL
,	NULL
30	NULL
mg	NULL
of	NULL
gentamicin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
10	NULL
mM	NULL
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic	NULL
acid	NULL
(	NULL
HEPES	NULL
)	NULL
buffer	NULL
.	NULL

voL	NULL
.	NULL

70	NULL
,	NULL
1996	NULL
Virus	NULL
production	NULL
.	NULL

HHV-6	NULL
(	NULL
GS	NULL
strain	NULL
)	NULL
was	NULL
propagated	NULL
in	NULL
HSB-2	NULL
cells	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
16	NULL
)	NULL
.	NULL

The	NULL
HHV-6	NULL
titer	NULL
,	NULL
expressed	NULL
as	NULL
the	NULL
50	NULL
%	NULL
tissue	NULL
culture	NULL
infective	NULL
dose	NULL
,	NULL
was	NULL
determined	NULL
by	NULL
scoring	NULL
the	NULL
number	NULL
of	NULL
HSB-2	NULL
cells	NULL
exhibiting	NULL
cytopathic	NULL
effect	NULL
.	NULL

The	NULL
virus	NULL
stock	NULL
had	NULL
a	NULL
titer	NULL
of	NULL
10°	NULL
50	NULL
%	NULL
infective	NULL
doses	NULL
per	NULL
ml	NULL
.	NULL

The	NULL
mock-infected	NULL
control	NULL
was	NULL
prepared	NULL
from	NULL
uninfected	NULL
HSB-2	NULL
culture	NULL
super-natant	NULL
.	NULL

Infection	NULL
of	NULL
cell	NULL
lines	NULL
.	NULL

Cells	NULL
(	NULL
10	NULL
'	NULL
)	NULL
were	NULL
pelleted	NULL
and	NULL
cither	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
10°	NULL
50	NULL
%	NULL
tissue	NULL
culture	NULL
infective	NULL
doses	NULL
)	NULL
,	NULL
mock	NULL
infected	NULL
,	NULL
or	NULL
treated	NULL
with	NULL
UV-irradiated	NULL
or	NULL
heat-inactivated	NULL
HHV-6	NULL
for	NULL
2	NULL
h	NULL
at	NULL
37°C	NULL
;	NULL
subsequently	NULL
,	NULL
they	NULL
were	NULL
resuspended	NULL
in	NULL
10	NULL
ml	NULL
of	NULL
culture	NULL
medium	NULL
.	NULL

Virus	NULL
inactivation	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
16	NULL
)	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
phos-phonoacetic	NULL
acid	NULL
(	NULL
PAA	NULL
;	NULL
an	NULL
inhibitor	NULL
of	NULL
viral	NULL
DNA	NULL
polymerase	NULL
activity	NULL
)	NULL
for	NULL
1	NULL
h	NULL
prior	NULL
to	NULL
infection	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
harvested	NULL
at	NULL
various	NULL
time	NULL
points	NULL
,	NULL
washed	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
;	NULL
pH	NULL
7.4	NULL
)	NULL
and	NULL
processed	NULL
for	NULL
RNA	NULL
isolation	NULL
,	NULL
fluorescence	NULL
microscopy	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
assays	NULL
,	NULL
and	NULL
gel	NULL
mobility	NULL
retardation	NULL
assays	NULL
.	NULL

RNA	NULL
isolation	NULL
and	NULL
Northern	NULL
(	NULL
RNA	NULL
)	NULL
blot	NULL
analysis	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
isolated	NULL
by	NULL
guanidium	NULL
isothyocyanate-phenol-chloroform	NULL
extraction	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
separated	NULL
by	NULL
electrophoresis	NULL
through	NULL
a	NULL
1	NULL
%	NULL
agarose	NULL
gel	NULL
containing	NULL
formaldehyde	NULL
.	NULL

RNA	NULL
was	NULL
transferred	NULL
onto	NULL
nylon	NULL
membranes	NULL
and	NULL
UV	NULL
cross-linked	NULL
before	NULL
prehybridization	NULL
in	NULL
5	NULL
%	NULL
SSPE	NULL
(	NULL
1x	NULL
SSPE	NULL
is	NULL
0.18	NULL
M	NULL
NaCl	NULL
,	NULL
10	NULL
mM	NULL
NaH	NULL
,	NULL
PO	NULL
,	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
EDTA	NULL
[	NULL
pH	NULL
7.7	NULL
]	NULL
)	NULL
-50	NULL
%	NULL
formamide-5x	NULL
Denhardt	NULL
's	NULL
solution-100	NULL
pg	NULL
of	NULL
denatured	NULL
salmon	NULL
sperm	NULL
DNA	NULL
per	NULL
ml-0.5	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
at	NULL
42°C	NULL
for	NULL
2	NULL
h.	NULL
Membranes	NULL
were	NULL
probed	NULL
for	NULL
BZLF1	NULL
and	NULL
glycer-aldchyde-3-phosphate	NULL
dehydrogenase	NULL
(	NULL
GAPDH	NULL
)	NULL
mRNA	NULL
with	NULL
*°P-labelled	NULL
probes	NULL
.	NULL

BZLF1	NULL
probe	NULL
corresponds	NULL
to	NULL
the	NULL
BamHI	NULL
Z	NULL
fragment	NULL
of	NULL
EBV	NULL
genome	NULL
,	NULL
and	NULL
GAPDH	NULL
probe	NULL
corresponds	NULL
to	NULL
the	NULL
cDNA	NULL
of	NULL
the	NULL
gene	NULL
.	NULL

Following	NULL
overnight	NULL
incubation	NULL
at	NULL
42°C	NULL
,	NULL
membranes	NULL
were	NULL
washed	NULL
twice	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
6	NULL
%	NULL
SSPE-0.5	NULL
%	NULL
SDS	NULL
and	NULL
twice	NULL
at	NULL
42°C	NULL
in	NULL
1	NULL
%	NULL
SSPE-0.1	NULL
%	NULL
SDS	NULL
before	NULL
being	NULL
exposed	NULL
to	NULL
film	NULL
at	NULL
-80°C	NULL
.	NULL

Immunofluorescence	NULL
assays	NULL
.	NULL

PBS-washed	NULL
Raji	NULL
cells	NULL
were	NULL
processed	NULL
for	NULL
immunofluorescence	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Following	NULL
1	NULL
h	NULL
of	NULL
incubation	NULL
with	NULL
the	NULL
BZ.1	NULL
anti-Zebra	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
L.	NULL
S.	NULL
Young	NULL
and	NULL
M.	NULL
Rowe	NULL
)	NULL
or	NULL
2D6	NULL
anti-HHV-6	NULL
gp105/82	NULL
(	NULL
gift	NULL
from	NULL
N.	NULL
Balachandran	NULL
)	NULL
monoclonal	NULL
antibodies	NULL
,	NULL
slides	NULL
were	NULL
washed	NULL
in	NULL
PBS	NULL
,	NULL
and	NULL
the	NULL
fluorescein-conjugated	NULL
goat	NULL
anti-mouse	NULL
IgG	NULL
secondary	NULL
antibody	NULL
(	NULL
Ortho	NULL
Diagnostics	NULL
,	NULL
Raritan	NULL
,	NULL
N.J.	NULL
)	NULL
was	NULL
added	NULL
for	NULL
1	NULL
h.	NULL
The	NULL
slides	NULL
were	NULL
then	NULL
washed	NULL
,	NULL
mounted	NULL
,	NULL
and	NULL
examined	NULL
in	NULL
a	NULL
Zeiss	NULL
Axioskop	NULL
fluorescence	NULL
microscopy	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
positive	NULL
cells	NULL
was	NULL
calculated	NULL
after	NULL
counting	NULL
at	NULL
least	NULL
200	NULL
cells	NULL
.	NULL

Statistical	NULL
significance	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
y*-test	NULL
.	NULL

A	NULL
P	NULL
value	NULL
of	NULL
<	NULL
0.05	NULL
was	NULL
considered	NULL
significant	NULL
.	NULL

CAT	NULL
assays	NULL
.	NULL

Cells	NULL
(	NULL
10	NULL
``	NULL
)	NULL
were	NULL
transfected	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
procedure	NULL
.	NULL

Briefly	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
TD	NULL
(	NULL
20	NULL
mM	NULL
Tris-HCl	NULL
[	NULL
pH	NULL
7.4	NULL
]	NULL
,	NULL
137	NULL
mM	NULL
NaC	NULL
)	NULL
,	NULL
5	NULL
mM	NULL
KCI	NULL
,	NULL
0.37	NULL
mM	NULL
Na	NULL
,	NULL
HPO	NULL
,	NULL
+	NULL
H	NULL
,	NULL
O	NULL
,	NULL
50	NULL
mM	NULL
MgCl	NULL
,	NULL
90	NULL
mM	NULL
CaCl	NULL
;	NULL
)	NULL
.	NULL

Cell	NULL
pellets	NULL
were	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
TD	NULL
containing	NULL
500	NULL
ug	NULL
of	NULL
DEAE-dextran	NULL
(	NULL
Pharma-cia	NULL
,	NULL
Dorval	NULL
,	NULL
Canada	NULL
)	NULL
and	NULL
plasmid	NULL
DNA	NULL
(	NULL
1	NULL
to	NULL
10	NULL
ag	NULL
)	NULL
and	NULL
then	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
20	NULL
min	NULL
,	NULL
after	NULL
which	NULL
10	NULL
ml	NULL
of	NULL
medium	NULL
containing	NULL
100	NULL
wM	NULL
chloroquine	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
Mo	NULL
.	NULL
)	NULL

was	NULL
added	NULL
.	NULL

Following	NULL
a	NULL
45-min	NULL
incubation	NULL
at	NULL
37°C	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
pelleted	NULL
and	NULL
resuspended	NULL
in	NULL
fresh	NULL
culture	NULL
medium	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
allowed	NULL
to	NULL
recover	NULL
for	NULL
24	NULL
h	NULL
before	NULL
being	NULL
infected	NULL
with	NULL
HHV-6	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Infection	NULL
was	NULL
allowed	NULL
to	NULL
proceed	NULL
for	NULL
24	NULL
to	NULL
72	NULL
h	NULL
before	NULL
CAT	NULL
activity	NULL
was	NULL
determined	NULL
.	NULL

The	NULL
fold	NULL
induction	NULL
in	NULL
CAT	NULL
activity	NULL
was	NULL
determined	NULL
by	NULL
scanning	NULL
densitometry	NULL
of	NULL
the	NULL
exposed	NULL
films	NULL
or	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
of	NULL
acetylated	NULL
chloramphenicol	NULL
.	NULL

All	NULL
CAT	NULL
constructs	NULL
used	NULL
were	NULL
generously	NULL
given	NULL
by	NULL
E.	NULL
Flemington	NULL
,	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Boston	NULL
,	NULL
Mass	NULL
.	NULL

;	NULL
these	NULL
include	NULL
-221Zpcat	NULL
,	NULL
-221	NULL
MII	NULL
Zpcat	NULL
,	NULL
-159Zpcat	NULL
,	NULL
-129Zpcat	NULL
,	NULL
-105Zpcat	NULL
,	NULL
-105	NULL
MII	NULL
Zpcat	NULL
,	NULL
-86Zpcat	NULL
,	NULL
-65Zpcat	NULL
,	NULL
BG-cat	NULL
,	NULL
and	NULL
ZII	NULL
BG-cat	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Luciferase	NULL
assays	NULL
.	NULL

For	NULL
greater	NULL
sensitivity	NULL
,	NULL
the	NULL
-86ZpCat	NULL
and	NULL
-65ZpCat	NULL
reporter	NULL
vectors	NULL
were	NULL
converted	NULL
to	NULL
-86Zpluc	NULL
and	NULL
-65Zpluc	NULL
,	NULL
respectively	NULL
,	NULL
by	NULL
deleting	NULL
the	NULL
CAT	NULL
gene	NULL
and	NULL
replacing	NULL
it	NULL
with	NULL
the	NULL
luciferase	NULL
gene	NULL
.	NULL

These	NULL
constructs	NULL
were	NULL
cotransfected	NULL
with	NULL
expression	NULL
vectors	NULL
encoding	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
protein	NULL
kinase	NULL
A	NULL
(	NULL
PKA	NULL
)	NULL
(	NULL
provided	NULL
by	NULL
S.	NULL
McKnight	NULL
[	NULL
46	NULL
]	NULL
)	NULL
and	NULL
GALA-CREB	NULL
proteins	NULL
(	NULL
provided	NULL
by	NULL
R.	NULL
A.	NULL
Maurer	NULL
[	NULL
50	NULL
]	NULL
)	NULL
.	NULL

At	NULL
72	NULL
h	NULL
posttransfection	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
,	NULL
counted	NULL
,	NULL
and	NULL
lysed	NULL
for	NULL
15	NULL
min	NULL
in	NULL
500	NULL
pl	NULL
of	NULL
buffer	NULL
(	NULL
25	NULL
mM	NULL
Tris	NULL
[	NULL
pH	NULL
7.8	NULL
]	NULL
,	NULL
2	NULL
mM	NULL
EDTA	NULL
,	NULL
2	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
)	NULL
.	NULL

After	NULL
brief	NULL
centrifugation	NULL
,	NULL
20-pl	NULL
volumes	NULL
of	NULL
each	NULL
sample	NULL
,	NULL
in	NULL
triplicate	NULL
,	NULL
were	NULL
tested	NULL
for	NULL
luciferase	NULL
activity	NULL
on	NULL
a	NULL
Biolumat	NULL
LB9500C	NULL
luminometer	NULL
(	NULL
Berthold	NULL
Analytical	NULL
Instruments	NULL
Inc.	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

Jurkat	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10	NULL
``	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
either	NULL
mock	NULL
infection	NULL
fluid	NULL
,	NULL
HHV-6	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
TCID3	NULL
,	NULL
)	NULL
,	NULL
or	NULL
TPA	NULL
(	NULL
50	NULL
ng/ml	NULL
)	NULL
for	NULL
periods	NULL
varying	NULL
from	NULL
1	NULL
to	NULL
8	NULL
h	NULL
,	NULL
after	NULL
which	NULL
nuclear	NULL
extracts	NULL
were	NULL
obtained	NULL
essentially	NULL
as	NULL
described	NULL
by	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

(	NULL
14	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
ice-cold	NULL
PBS	NULL
and	NULL
resuspended	NULL
in	NULL
hypotonic	NULL
buffer	NULL
(	NULL
buffer	NULL
A	NULL
of	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

[	NULL
14	NULL
]	NULL
)	NULL
.	NULL

Cytoplasmic	NULL
membranes	NULL
were	NULL
ruptured	NULL
by	NULL
addition	NULL
of	NULL
0.5	NULL
%	NULL
Nonidet	NULL
P-40	NULL
(	NULL
final	NULL
concentration	NULL
)	NULL
.	NULL

Nuclei	NULL
were	NULL
pelleted	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
2	NULL
volumes	NULL
of	NULL
buffer	NULL
C	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Extracts	NULL
were	NULL
incubated	NULL
at	NULL
4°C	NULL
for	NULL
1	NULL
h	NULL
,	NULL
after	NULL
which	NULL
the	NULL
samples	NULL
were	NULL
centrifuged	NULL
at	NULL
100,000	NULL
x	NULL
g	NULL
for	NULL
30	NULL
min	NULL
.	NULL

Supernatants	NULL
containing	NULL
nuclear	NULL
proteins	NULL
were	NULL
diluted	NULL
with	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
buffer	NULL
D	NULL
,	NULL
and	NULL
the	NULL
protein	NULL
concentration	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
bicinchoninic	NULL
acid	NULL
protein	NULL
assay	NULL
(	NULL
Pierce	NULL
,	NULL
Rockford	NULL
,	NULL
III	NULL
.	NULL
)	NULL

before	NULL
the	NULL
samples	NULL
were	NULL
frozen	NULL
at	NULL
-80°C	NULL
.	NULL

Typical	NULL
binding	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
as	NULL
follows	NULL
.	NULL

Protein	NULL
(	NULL
2	NULL
pg	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
3	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Pharmacia	NULL
)	NULL
,	NULL
with	NULL
or	NULL
without	NULL
unlabelled	NULL
ZII	NULL
(	NULL
40	NULL
ng	NULL
)	NULL
(	NULL
5'-CCCAAACCATGACATCACAGAG-3	NULL
``	NULL
)	NULL
,	NULL
CRE	NULL
(	NULL
5	NULL
``	NULL
-GATCCGGCTGACGT	NULL
EBV	NULL
ZEBRA	NULL
PROMOTER	NULL
ACTIVATION	NULL
BY	NULL
HHV-6	NULL
1785	NULL
wlvl	NULL
H	NULL
M	NULL
E	NULL
IQAUAPIOIaIMI	NULL
SlL	NULL
1	NULL
E	NULL
IZ	NULL
IR	NULL
!	NULL

K	NULL
F0	NULL
u	NULL
J	NULL
'	NULL
T	NULL
BZLF1	NULL
+	NULL
BRLF1	NULL
B	NULL
HHV-6	NULL
x	NULL
©	NULL
in	NULL
©	NULL
=	NULL
=	NULL
o	NULL
=	NULL
B4	NULL
E	NULL
T	NULL
I	NULL
<	NULL
I	NULL
I	NULL
I	NULL
§	NULL
a	NULL
%	NULL
&	NULL
S	NULL
&	NULL
&	NULL
28	NULL
S	NULL
im	NULL
#	NULL
4	NULL
ﬂ	NULL
¥	NULL
U	NULL
w	NULL
_C	NULL
&	NULL
a	NULL
#	NULL
»	NULL
**	NULL
wh	NULL
@	NULL
BZLFi	NULL
+BALF1	NULL
18	NULL
Sim	NULL
w	NULL
‘	NULL
-	NULL
%	NULL
BZLF1	NULL
«	NULL
ai	NULL
GAPDH	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Kinetics	NULL
of	NULL
BZLF1	NULL
RNA	NULL
expression	NULL
following	NULL
infection	NULL
of	NULL
Raji	NULL
cells	NULL
with	NULL
HHV-6	NULL
.	NULL

Raji	NULL
cells	NULL
(	NULL
10	NULL
``	NULL
)	NULL
were	NULL
either	NULL
treated	NULL
with	NULL
mock	NULL
infection	NULL
fluid	NULL
,	NULL
infected	NULL
with	NULL
HHV-6	NULL
,	NULL
or	NULL
stimulated	NULL
with	NULL
TPA	NULL
for	NULL
various	NULL
periods	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
isolated	NULL
and	NULL
separated	NULL
by	NULL
electrophoresis	NULL
in	NULL
a	NULL
formaldehyde-containing	NULL
agarose	NULL
gel	NULL
.	NULL

Following	NULL
transfer	NULL
,	NULL
RNA	NULL
was	NULL
probed	NULL
for	NULL
BZLF1	NULL
mRNA	NULL
by	NULL
using	NULL
the	NULL
*°P-labelled	NULL
BamHI	NULL
Z	NULL
genomic	NULL
fragment	NULL
of	NULL
EBV	NULL
and	NULL
for	NULL
the	NULL
housekeeping	NULL
GAPDH	NULL
mRNA	NULL
.	NULL

(	NULL
A	NULL
)	NULL
BamHI	NULL
restriction	NULL
map	NULL
of	NULL
the	NULL
EBV	NULL
genome	NULL
along	NULL
with	NULL
the	NULL
two	NULL
sites	NULL
(	NULL
from	NULL
Z	NULL
and	NULL
R	NULL
promoters	NULL
)	NULL
of	NULL
initiation	NULL
of	NULL
the	NULL
BZLF1	NULL
mRNA	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Expression	NULL
of	NULL
BZLF1	NULL
,	NULL
BZLFI	NULL
plus	NULL
BRLF1	NULL
,	NULL
and	NULL
GAPDH	NULL
mRNAs	NULL
after	NULL
infection	NULL
by	NULL
HHV-6	NULL
.	NULL

CATCAGCTA-3	NULL
'	NULL
)	NULL
,	NULL
or	NULL
AP-1	NULL
(	NULL
5	NULL
%	NULL
-CGGTTGATGAGTCAGCCGGAA-3	NULL
'	NULL
)	NULL
dou-ble-stranded	NULL
oligonucleotides	NULL
for	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

*°P-end-labelled	NULL
ZII	NULL
,	NULL
CRE	NULL
,	NULL
or	NULL
AP-1	NULL
oligonucleotides	NULL
(	NULL
0.2	NULL
ng	NULL
)	NULL
were	NULL
added	NULL
,	NULL
and	NULL
the	NULL
mixtures	NULL
were	NULL
left	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
30	NULL
min	NULL
before	NULL
being	NULL
loaded	NULL
onto	NULL
a	NULL
5	NULL
%	NULL
nondenaturing	NULL
Tris-glycine	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

Migration	NULL
was	NULL
carried	NULL
out	NULL
at	NULL
60	NULL
mA	NULL
,	NULL
and	NULL
the	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
exposed	NULL
to	NULL
X-ray	NULL
films	NULL
.	NULL

Supershift	NULL
experiments	NULL
were	NULL
performed	NULL
essentially	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Following	NULL
the	NULL
30-min	NULL
incubation	NULL
,	NULL
antibodies	NULL
(	NULL
1	NULL
pl	NULL
)	NULL
against	NULL
CREB	NULL
protein	NULL
,	NULL
binding	NULL
to	NULL
residues	NULL
92	NULL
to	NULL
124	NULL
in	NULL
the	NULL
P-box	NULL
region	NULL
of	NULL
CREB	NULL
327	NULL
(	NULL
42	NULL
,	NULL
52	NULL
;	NULL
a	NULL
gift	NULL
from	NULL
J.	NULL
Habener	NULL
,	NULL
Massachusetts	NULL
General	NULL
Hospital	NULL
,	NULL
Boston	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

,	NULL
or	NULL
antibodies	NULL
directed	NULL
against	NULL
c-fos	NULL
or	NULL
c-jun	NULL
(	NULL
Oncogene	NULL
Science	NULL
)	NULL
were	NULL
mixed	NULL
with	NULL
samples	NULL
for	NULL
an	NULL
additional	NULL
30	NULL
min	NULL
before	NULL
electrophoresis	NULL
.	NULL

RESULTS	NULL
Kinetics	NULL
of	NULL
BZLF1	NULL
mRNA	NULL
expression	NULL
following	NULL
infection	NULL
of	NULL
Raji	NULL
cells	NULL
with	NULL
HHV-6	NULL
.	NULL

The	NULL
kinetics	NULL
of	NULL
BZLF1	NULL
gene	NULL
expression	NULL
was	NULL
examined	NULL
following	NULL
infection	NULL
of	NULL
Raji	NULL
cells	NULL
with	NULL
HHV-6	NULL
.	NULL

BZLF1	NULL
is	NULL
an	NULL
immediate-early	NULL
gene	NULL
which	NULL
is	NULL
expressed	NULL
rapidly	NULL
following	NULL
stimulation	NULL
of	NULL
EBV	NULL
genome-positive	NULL
B	NULL
cells	NULL
.	NULL

RNA	NULL
was	NULL
extracted	NULL
beginning	NULL
at	NULL
2	NULL
h	NULL
after	NULL
HHV-6	NULL
infection	NULL
and	NULL
up	NULL
to	NULL
24	NULL
h.	NULL
Results	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
indicate	NULL
that	NULL
as	NULL
soon	NULL
as	NULL
2	NULL
h	NULL
postinfection	NULL
,	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
BZLF1	NULL
mRNA	NULL
level	NULL
is	NULL
observed	NULL
.	NULL

The	NULL
probe	NULL
used	NULL
,	NULL
BamHI	NULL
Z	NULL
fragment	NULL
of	NULL
EBV	NULL
genome	NULL
,	NULL
recognizes	NULL
both	NULL
the	NULL
monocistronic	NULL
BZLF1	NULL
and	NULL
bicistronic	NULL
BZLFI-BRLF1	NULL
mRNAs	NULL
,	NULL
transcribed	NULL
from	NULL
the	NULL
Z	NULL
and	NULL
R	NULL
promoters	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

Increased	NULL
expression	NULL
of	NULL
BZLF1	NULL
mRNA	NULL
was	NULL
also	NULL
observed	NULL
at	NULL
4	NULL
h	NULL
postinfection	NULL
,	NULL
after	NULL
which	NULL
time	NULL
a	NULL
slow	NULL
decrease	NULL
in	NULL
BZLF1	NULL
expres-	NULL
1786	NULL
FLAMAND	NULL
AND	NULL
MENEZES	NULL
Fold	NULL
increase	NULL
in	NULL
Cat	NULL
activity	NULL
Rail	NULL
-65ZpCavHHV-6	NULL
|	NULL
wwp	NULL
-	NULL
1	NULL
Mock	NULL
a	NULL
0	NULL
HHvG	NULL
24	NULL
His	NULL
.	NULL

800	NULL
®	NULL
#	NULL
22	NULL
HHV-6	NULL
48	NULL
His	NULL
-	NULL
wl	NULL
_	NULL
CP	NULL
‘	NULL
._	NULL
56	NULL
y	NULL
g	NULL
hvo	NULL
2	NULL
hs	NULL
_	NULL
wl	NULL
)	NULL
_	NULL
W	NULL
‘	NULL
i	NULL
&	NULL
3	NULL
%	NULL
.	NULL

HHV-6	NULL
U.V	NULL
.	NULL

~-	NULL
<	NULL
@	NULL
0	NULL
--	NULL
-	NULL
@	NULL
°	NULL
pZVH14	NULL
pzvezo	NULL
>	NULL
~	NULL
<	NULL
~	NULL
@	NULL
0	NULL
Cat	NULL
*	NULL
a	NULL
75	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Zebra	NULL
promoter	NULL
activity	NULL
in	NULL
Raji	NULL
cells	NULL
following	NULL
infection	NULL
with	NULL
HHV-6	NULL
.	NULL

Raji	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
Zebra	NULL
promoter	NULL
(	NULL
-221Zpcat	NULL
and	NULL
-65Zpcat	NULL
)	NULL
constructs	NULL
,	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
live	NULL
HHV-6	NULL
or	NULL
UV-irradiated	NULL
HHV-6	NULL
for	NULL
various	NULL
periods	NULL
,	NULL
after	NULL
which	NULL
CAT	NULL
activity	NULL
was	NULL
determined	NULL
.	NULL

Raji	NULL
cells	NULL
were	NULL
also	NULL
cotransfected	NULL
with	NULL
-221Zpcat	NULL
and	NULL
pZVB70	NULL
or	NULL
pZVH14	NULL
.	NULL

Purified	NULL
CAT	NULL
enzyme	NULL
was	NULL
included	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
.	NULL

Fold	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
was	NULL
determined	NULL
by	NULL
scanning	NULL
densitometry	NULL
of	NULL
the	NULL
autoradiographs	NULL
.	NULL

Data	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

sion	NULL
was	NULL
noted	NULL
.	NULL

TPA-stimulated	NULL
Raji	NULL
cells	NULL
(	NULL
2	NULL
h	NULL
)	NULL
were	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
GAPDH	NULL
housekeeping	NULL
gene	NULL
is	NULL
also	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
.	NULL

Zebra	NULL
protein	NULL
expression	NULL
following	NULL
infection	NULL
of	NULL
Raji	NULL
cells	NULL
with	NULL
HHV-6	NULL
.	NULL

To	NULL
ascertain	NULL
that	NULL
HHV-6-induced	NULL
BZLF1	NULL
gene	NULL
expression	NULL
was	NULL
correlated	NULL
with	NULL
an	NULL
increase	NULL
in	NULL
Zebra	NULL
protein	NULL
,	NULL
HHV-6-infected	NULL
Raji	NULL
cells	NULL
were	NULL
processed	NULL
at	NULL
24	NULL
h	NULL
for	NULL
immunofluorescence	NULL
and	NULL
analyzed	NULL
for	NULL
Zebra	NULL
expression	NULL
.	NULL

On	NULL
aver-age	NULL
,	NULL
6	NULL
to	NULL
8	NULL
%	NULL
of	NULL
Raji	NULL
cells	NULL
were	NULL
positive	NULL
for	NULL
Zebra	NULL
antigen	NULL
following	NULL
infection	NULL
with	NULL
HHV-6	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
represents	NULL
a	NULL
greater	NULL
than	NULL
10-fold	NULL
increase	NULL
in	NULL
Zebra-positive	NULL
cells	NULL
compared	NULL
with	NULL
mock-infected	NULL
ones	NULL
.	NULL

Approximately	NULL
25	NULL
%	NULL
of	NULL
Raji	NULL
cells	NULL
were	NULL
found	NULL
to	NULL
react	NULL
with	NULL
the	NULL
BZ.1	NULL
anti-Zebra	NULL
monoclonal	NULL
antibody	NULL
following	NULL
TPA	NULL
treatment	NULL
(	NULL
positive	NULL
control	NULL
)	NULL
.	NULL

HHV-6	NULL
infection	NULL
of	NULL
Raji	NULL
cells	NULL
was	NULL
confirmed	NULL
by	NULL
detecting	NULL
gp105/82	NULL
of	NULL
HHV	NULL
-6	NULL
with	NULL
the	NULL
2D6	NULL
monoclonal	NULL
antibody	NULL
.	NULL

Strong	NULL
cytoplasmic	NULL
staining	NULL
was	NULL
seen	NULL
in	NULL
HHV-6-infected	NULL
cells	NULL
,	NULL
of	NULL
which	NULL
between	NULL
20	NULL
and	NULL
30	NULL
%	NULL
were	NULL
positive	NULL
for	NULL
gp105/82	NULL
of	NULL
HHV-6	NULL
.	NULL

Zp	NULL
activation	NULL
following	NULL
infection	NULL
with	NULL
HHV-6	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
HHV-6	NULL
infection	NULL
of	NULL
Raji	NULL
cells	NULL
results	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
BZLF1	NULL
mRNA	NULL
and	NULL
Zebra	NULL
protein	NULL
expression	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
HHV-6	NULL
had	NULL
any	NULL
effect	NULL
on	NULL
Zp	NULL
of	NULL
EBV	NULL
,	NULL
Raji	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
two	NULL
CAT	NULL
constructs	NULL
,	NULL
one	NULL
containing	NULL
the	NULL
full	NULL
Zp	NULL
(	NULL
-221	NULL
to	NULL
+12	NULL
from	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
)	NULL
(	NULL
-221	NULL
Zpcat	NULL
)	NULL
and	NULL
the	NULL
other	NULL
containing	NULL
65	NULL
nucleotides	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
initiation	NULL
site	NULL
(	NULL
-65Zpcat	NULL
)	NULL
.	NULL

Results	NULL
indicate	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
that	NULL
HHV-6	NULL
activates	NULL
the	NULL
full	NULL
Zp	NULL
(	NULL
-221Zpcat	NULL
)	NULL
whereas	NULL
it	NULL
has	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
5'-deleted	NULL
-65Zpcat	NULL
.	NULL

Kinetics	NULL
of	NULL
infection	NULL
indicate	NULL
that	NULL
maximal	NULL
Zp	NULL
activation	NULL
(	NULL
56-fold	NULL
)	NULL
occurs	NULL
within	NULL
48	NULL
h.	NULL
Furthermore	NULL
,	NULL
we	NULL
tested	NULL
whether	NULL
viral	NULL
infectivity	NULL
was	NULL
required	NULL
to	NULL
observe	NULL
Zp	NULL
activation	NULL
.	NULL

UV-irradiated	NULL
HHV-6	NULL
failed	NULL
to	NULL
stimulate	NULL
Zp	NULL
to	NULL
any	NULL
extent	NULL
,	NULL
indicating	NULL
the	NULL
need	NULL
for	NULL
infectious	NULL
virus	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
heat-inactivated	NULL
virus	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Cotransfection	NULL
of	NULL
J.	NULL
ViroL	NULL
.	NULL

-221Zpcat	NULL
with	NULL
pZVB70	NULL
or	NULL
pZVH14	NULL
genomic	NULL
segments	NULL
of	NULL
HHV-6	NULL
,	NULL
which	NULL
are	NULL
known	NULL
to	NULL
transactivate	NULL
various	NULL
heterologous	NULL
promoters	NULL
such	NULL
as	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
,	NULL
failed	NULL
to	NULL
stimulate	NULL
Zp	NULL
of	NULL
EBV	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
five	NULL
other	NULL
HHV-6	NULL
genomic	NULL
segments	NULL
,	NULL
some	NULL
of	NULL
which	NULL
encode	NULL
immediate-early	NULL
proteins	NULL
,	NULL
known	NULL
to	NULL
transactivate	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
,	NULL
were	NULL
tested	NULL
and	NULL
found	NULL
not	NULL
to	NULL
activate	NULL
Zp	NULL
to	NULL
any	NULL
extent	NULL
.	NULL

These	NULL
were	NULL
pEPLF3	NULL
,	NULL
pIEGP2-3	NULL
'	NULL
,	NULL
pIEG1-2	NULL
,	NULL
pBCLFO/1	NULL
(	NULL
obtained	NULL
from	NULL
J.	NULL
Nicholas	NULL
)	NULL
,	NULL
and	NULL
B115	NULL
(	NULL
obtained	NULL
from	NULL
A.	NULL
Razzaque	NULL
)	NULL
.	NULL

Purified	NULL
CAT	NULL
enzyme	NULL
was	NULL
included	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
of	NULL
assay	NULL
reactions	NULL
.	NULL

Effect	NULL
of	NULL
the	NULL
viral	NULL
DNA	NULL
polymerase	NULL
inhibitor	NULL
PAA	NULL
on	NULL
Zp	NULL
activation	NULL
by	NULL
HHV-6	NULL
.	NULL

All	NULL
previous	NULL
transfection	NULL
experiments	NULL
were	NULL
performed	NULL
with	NULL
Raji	NULL
cells	NULL
.	NULL

Since	NULL
it	NULL
is	NULL
known	NULL
that	NULL
Zebra	NULL
can	NULL
transactivate	NULL
its	NULL
own	NULL
promoter	NULL
(	NULL
19	NULL
)	NULL
,	NULL
all	NULL
subsequent	NULL
transfection	NULL
experiments	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
EBV-negative	NULL
Jurkat	NULL
T-cell	NULL
line	NULL
.	NULL

Our	NULL
results	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
indicate	NULL
that	NULL
transfection	NULL
of	NULL
-221Zpcat	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
followed	NULL
by	NULL
infection	NULL
by	NULL
HHV-6	NULL
,	NULL
leads	NULL
to	NULL
levels	NULL
of	NULL
Zp	NULL
activation	NULL
similar	NULL
to	NULL
those	NULL
observed	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

Second	NULL
,	NULL
knowing	NULL
that	NULL
HHV-6	NULL
infectivity	NULL
is	NULL
required	NULL
to	NULL
activate	NULL
Zp	NULL
of	NULL
EBV	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
effect	NULL
of	NULL
PAA	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
Zp	NULL
by	NULL
HHV-6	NULL
.	NULL

The	NULL
results	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
suggest	NULL
that	NULL
Zp	NULL
is	NULL
activated	NULL
by	NULL
HHV-6	NULL
in	NULL
both	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
PAA	NULL
.	NULL

Different	NULL
concentrations	NULL
of	NULL
PAA	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
ability	NULL
of	NULL
HHV-6	NULL
to	NULL
stimulate	NULL
Zp	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
Zp	NULL
region	NULL
(	NULL
s	NULL
)	NULL
essential	NULL
for	NULL
activation	NULL
by	NULL
HHV-6	NULL
.	NULL

The	NULL
Zp	NULL
contains	NULL
multiple	NULL
domains	NULL
,	NULL
some	NULL
of	NULL
which	NULL
are	NULL
responsive	NULL
to	NULL
TPA-inducible	NULL
factors	NULL
while	NULL
others	NULL
bind	NULL
Zebra	NULL
itself	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
minimal	NULL
promoter	NULL
required	NULL
for	NULL
Zp	NULL
activation	NULL
by	NULL
HHV-6	NULL
,	NULL
we	NULL
have	NULL
transfected	NULL
a	NULL
series	NULL
of	NULL
5'-deleted	NULL
Zp	NULL
constructs	NULL
into	NULL
T	NULL
cells	NULL
and	NULL
tested	NULL
them	NULL
for	NULL
responsiveness	NULL
to	NULL
infection	NULL
by	NULL
HHV-6	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
all	NULL
Zp	NULL
constructs	NULL
,	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
-65	NULL
Zpcat	NULL
,	NULL
were	NULL
activated	NULL
following	NULL
infection	NULL
with	NULL
HHV-6	NULL
.	NULL

There	NULL
were	NULL
no	NULL
differences	NULL
in	NULL
CAT	NULL
activity	NULL
between	NULL
the	NULL
various	NULL
Zp	NULL
constructs	NULL
(	NULL
from	NULL
-221	NULL
to	NULL
-86	NULL
)	NULL
.	NULL

Transfection	NULL
of	NULL
different	NULL
quantities	NULL
(	NULL
1	NULL
to	NULL
10	NULL
ug	NULL
)	NULL
of	NULL
-86Zpcat	NULL
plasmid	NULL
into	NULL
Jurkat	NULL
cells	NULL
followed	NULL
by	NULL
infection	NULL
with	NULL
HHV-6	NULL
led	NULL
to	NULL
a	NULL
plateau	NULL
in	NULL
promoter	NULL
activity	NULL
response	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
plasmid	NULL
DNA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Having	NULL
determined	NULL
that	NULL
the	NULL
minimal	NULL
promoter	NULL
responsive	NULL
to	NULL
HHV-6	NULL
contains	NULL
86	NULL
nucleotides	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
,	NULL
we	NULL
next	NULL
studied	NULL
the	NULL
potentially	NULL
important	NULL
sites	NULL
within	NULL
this	NULL
region	NULL
.	NULL

Sequence	NULL
analysis	NULL
of	NULL
these	NULL
nucleotides	NULL
suggested	NULL
Jurkat	NULL
Fold	NULL
increase	NULL
in	NULL
Cat	NULL
activity	NULL
Mock	NULL
0	NULL
HHV-6	NULL
#	NULL
32	NULL
n	NULL
HHV-6+PAA	NULL
200	NULL
ug/m	NULL
!	NULL

§	NULL
n	NULL
+	NULL
ug/m	NULL
l	NULL
18	NULL
N	NULL
8	NULL
®	NULL
HHV-6+PAA	NULL
100	NULL
ug/ml	NULL
26	NULL
HHV-6+PAA	NULL
50	NULL
ug/ml	NULL
+	NULL
ug/im	NULL
33	NULL
b	NULL
4	NULL
bd	NULL
dd	NULL
HHV-6+PAA	NULL
25ng/ml	NULL
g	NULL
28	NULL
Cat	NULL
72	NULL
i	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Effect	NULL
of	NULL
PAA	NULL
on	NULL
Zebra	NULL
promoter	NULL
induction	NULL
by	NULL
HHV-6	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
-221Zpcat	NULL
plasmids	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
increasing	NULL
concentration	NULL
of	NULL
PAA	NULL
for	NULL
1	NULL
h	NULL
before	NULL
infection	NULL
with	NULL
HHV-6	NULL
.	NULL

After	NULL
48	NULL
h	NULL
,	NULL
cytoplasmic	NULL
extracts	NULL
from	NULL
cells	NULL
were	NULL
obtained	NULL
and	NULL
analyzed	NULL
for	NULL
CAT	NULL
activity	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
three	NULL
separate	NULL
experiments	NULL
.	NULL

voL	NULL
.	NULL

70	NULL
,	NULL
1996	NULL
[	NULL
]	NULL
Mock-infected	NULL
E	NULL
HHV-6-infected	NULL
Cat	NULL
activity	NULL
(	NULL
cpm	NULL
)	NULL
+221	NULL
+159	NULL
+105	NULL
-86	NULL
-65	NULL
-221M1l	NULL
BG	NULL
ZNBG	NULL
ZpCat	NULL
plasmids	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
minimal	NULL
Zebra	NULL
promoter	NULL
and	NULL
localization	NULL
of	NULL
the	NULL
Zp	NULL
domain	NULL
essential	NULL
for	NULL
EBV	NULL
activation	NULL
by	NULL
HHV-6	NULL
infection	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
a	NULL
series	NULL
of	NULL
5'-deleted	NULL
Zpcat	NULL
constructs	NULL
(	NULL
-221	NULL
to	NULL
-65	NULL
)	NULL
,	NULL
a	NULL
mutant	NULL
form	NULL
of	NULL
-221ZpCat	NULL
termed	NULL
-221	NULL
MII	NULL
Zpcat	NULL
,	NULL
a	NULL
minimal	NULL
B-globin	NULL
promoter	NULL
(	NULL
BG	NULL
)	NULL
,	NULL
and	NULL
the	NULL
BG	NULL
upstream	NULL
of	NULL
which	NULL
the	NULL
ZII	NULL
domain	NULL
of	NULL
Zp	NULL
was	NULL
cloned	NULL
(	NULL
ZIIBG	NULL
)	NULL
.	NULL

At	NULL
48	NULL
h	NULL
after	NULL
HHV-6	NULL
infection	NULL
,	NULL
CAT	NULL
activity	NULL
was	NULL
determined	NULL
in	NULL
each	NULL
sample	NULL
.	NULL

Data	NULL
shown	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
experiments	NULL
.	NULL

that	NULL
there	NULL
was	NULL
a	NULL
putative	NULL
AP-1	NULL
or	NULL
CRE	NULL
consensus	NULL
sequence	NULL
(	NULL
TGACATCA	NULL
)	NULL
located	NULL
between	NULL
-67	NULL
and	NULL
-60	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
importance	NULL
of	NULL
this	NULL
sequence	NULL
,	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
plasmids	NULL
containing	NULL
wild-type	NULL
and	NULL
mutated	NULL
AP-1/CRE	NULL
sites	NULL
(	NULL
ATTCATCA	NULL
)	NULL
(	NULL
-221MIIZpcat	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
wild-type	NULL
promoter	NULL
constructs	NULL
were	NULL
activated	NULL
severalfold	NULL
while	NULL
promoters	NULL
containing	NULL
a	NULL
mutated	NULL
AP-1/CRE	NULL
site	NULL
could	NULL
not	NULL
be	NULL
activated	NULL
following	NULL
infection	NULL
by	NULL
HHV-6	NULL
,	NULL
suggesting	NULL
that	NULL
this	NULL
region	NULL
of	NULL
Zp	NULL
is	NULL
essential	NULL
for	NULL
responsiveness	NULL
.	NULL

Furthermore	NULL
,	NULL
cloning	NULL
of	NULL
the	NULL
ZII	NULL
domain	NULL
of	NULL
Zp	NULL
,	NULL
containing	NULL
the	NULL
CRE/AP-1	NULL
sequences	NULL
,	NULL
upstream	NULL
of	NULL
the	NULL
minimal	NULL
BG	NULL
promoter	NULL
(	NULL
ZIIBG	NULL
)	NULL
was	NULL
able	NULL
to	NULL
restore	NULL
responsiveness	NULL
to	NULL
levels	NULL
similar	NULL
to	NULL
those	NULL
found	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
wild-type	NULL
Zp	NULL
following	NULL
HHV-6	NULL
infection	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
ZII	NULL
by	NULL
itself	NULL
is	NULL
sufficient	NULL
and	NULL
does	NULL
not	NULL
rely	NULL
on	NULL
any	NULL
cis-acting	NULL
elements	NULL
found	NULL
within	NULL
Zp	NULL
to	NULL
promoter	NULL
responsiveness	NULL
to	NULL
HHV-6	NULL
infection	NULL
.	NULL

ZII	NULL
domain	NULL
of	NULL
Zp	NULL
binds	NULL
noninducible	NULL
,	NULL
constitutively	NULL
ex-pressed	NULL
,	NULL
nuclear	NULL
factors	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
a	NULL
putative	NULL
AP-1/	NULL
CRE	NULL
site	NULL
essential	NULL
for	NULL
activation	NULL
by	NULL
HHV-6	NULL
led	NULL
us	NULL
to	NULL
study	NULL
proteins	NULL
capable	NULL
of	NULL
interacting	NULL
with	NULL
the	NULL
ZII	NULL
domain	NULL
.	NULL

Double-stranded	NULL
oligonucleotides	NULL
encompassing	NULL
the	NULL
AP-1/CRE	NULL
site	NULL
found	NULL
within	NULL
ZII	NULL
were	NULL
used	NULL
to	NULL
study	NULL
the	NULL
interaction	NULL
of	NULL
the	NULL
DNA-binding	NULL
protein	NULL
with	NULL
ZII	NULL
and	NULL
possibly	NULL
to	NULL
mediate	NULL
Zp	NULL
activation	NULL
.	NULL

By	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
,	NULL
it	NULL
was	NULL
observed	NULL
that	NULL
mock-	NULL
and	NULL
HHV-6-infected	NULL
Jurkat	NULL
cells	NULL
were	NULL
expressing	NULL
nuclear	NULL
proteins	NULL
capable	NULL
of	NULL
binding	NULL
to	NULL
the	NULL
ZII	NULL
oligonucleotides	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Two	NULL
distinct	NULL
complexes	NULL
with	NULL
different	NULL
electrophoretic	NULL
mobilities	NULL
were	NULL
observed	NULL
.	NULL

Protein	NULL
binding	NULL
was	NULL
specific	NULL
and	NULL
could	NULL
be	NULL
eliminated	NULL
by	NULL
preincubation	NULL
with	NULL
excess	NULL
unlabelled	NULL
ZII	NULL
oligonucleotides	NULL
.	NULL

Kinetic	NULL
studies	NULL
of	NULL
infection	NULL
did	NULL
not	NULL
lead	NULL
to	NULL
an	NULL
increase	NULL
in	NULL
binding	NULL
,	NULL
and	NULL
neither	NULL
did	NULL
cell	NULL
treatment	NULL
with	NULL
TPA	NULL
,	NULL
suggesting	NULL
that	NULL
proteins	NULL
binding	NULL
to	NULL
ZII	NULL
EBV	NULL
ZEBRA	NULL
PROMOTER	NULL
ACTIVATION	NULL
BY	NULL
HHV-6	NULL
1787	NULL
are	NULL
constitutively	NULL
expressed	NULL
and	NULL
are	NULL
not	NULL
induced	NULL
by	NULL
HHV-6	NULL
or	NULL
TPA	NULL
.	NULL

Binding	NULL
of	NULL
proteins	NULL
to	NULL
ZII	NULL
can	NULL
be	NULL
efficiently	NULL
inhibited	NULL
by	NULL
oligonucleotides	NULL
containing	NULL
CRE	NULL
consensus	NULL
sequences	NULL
.	NULL

To	NULL
characterize	NULL
further	NULL
the	NULL
constitutively	NULL
expressed	NULL
factors	NULL
capable	NULL
of	NULL
binding	NULL
to	NULL
ZII	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
ability	NULL
of	NULL
oligonucleotides	NULL
containing	NULL
CREB	NULL
(	NULL
5'-TGACGTCA-3	NULL
'	NULL
)	NULL
or	NULL
AP-1-binding	NULL
(	NULL
5'-TGAGTCA-3	NULL
'	NULL
)	NULL
sequences	NULL
to	NULL
compete	NULL
for	NULL
ZII	NULL
binding	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
4-h	NULL
HHV-6-infected	NULL
Jurkat	NULL
cells	NULL
were	NULL
found	NULL
to	NULL
contain	NULL
proteins	NULL
capable	NULL
of	NULL
binding	NULL
ZII	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Incubation	NULL
of	NULL
extracts	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
excess	NULL
unlabelled	NULL
ZII	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
CRE	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
oligonucleotides	NULL
was	NULL
found	NULL
to	NULL
reduce	NULL
binding	NULL
of	NULL
both	NULL
complexes	NULL
to	NULL
a	NULL
minimum	NULL
,	NULL
whereas	NULL
AP-1	NULL
oligonucleotides	NULL
did	NULL
not	NULL
affect	NULL
binding	NULL
of	NULL
proteins	NULL
to	NULL
the	NULL
more	NULL
slowly	NULL
migrating	NULL
(	NULL
upper	NULL
)	NULL
complex	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

CRE	NULL
oligonucleotides	NULL
were	NULL
at	NULL
least	NULL
as	NULL
efficient	NULL
as	NULL
ZII	NULL
in	NULL
competing	NULL
for	NULL
protein	NULL
binding	NULL
.	NULL

Having	NULL
determined	NULL
that	NULL
CRE	NULL
oligonucleotides	NULL
can	NULL
efficiently	NULL
compete	NULL
with	NULL
ZII	NULL
for	NULL
protein	NULL
binding	NULL
,	NULL
we	NULL
studied	NULL
proteins	NULL
within	NULL
the	NULL
same	NULL
extracts	NULL
capable	NULL
of	NULL
binding	NULL
to	NULL
CRE	NULL
.	NULL

As	NULL
shown	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
the	NULL
nuclear	NULL
extracts	NULL
contained	NULL
proteins	NULL
binding	NULL
to	NULL
CRE	NULL
oligonucleotides	NULL
.	NULL

However	NULL
,	NULL
with	NULL
equal	NULL
quantities	NULL
of	NULL
protein	NULL
,	NULL
more	NULL
binding	NULL
was	NULL
observed	NULL
with	NULL
the	NULL
CRE	NULL
oligonucleotides	NULL
than	NULL
with	NULL
those	NULL
bound	NULL
to	NULL
the	NULL
ZII	NULL
oligonucle-otide	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

The	NULL
electrophoretic	NULL
mobility	NULL
patterns	NULL
of	NULL
both	NULL
complexes	NULL
bound	NULL
to	NULL
CRE	NULL
were	NULL
identical	NULL
to	NULL
those	NULL
of	NULL
the	NULL
complexes	NULL
bound	NULL
to	NULL
ZII	NULL
.	NULL

Incubation	NULL
of	NULL
nuclear	NULL
extracts	NULL
with	NULL
excess	NULL
cold	NULL
ZII	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
partially	NULL
inhibited	NULL
binding	NULL
to	NULL
CRE	NULL
,	NULL
while	NULL
complete	NULL
removal	NULL
of	NULL
binding	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
excess	NULL
cold	NULL
CRE	NULL
oligonucleotides	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

Less	NULL
efficient	NULL
binding	NULL
to	NULL
and	NULL
competition	NULL
by	NULL
ZII	NULL
oligonucleotides	NULL
can	NULL
be	NULL
explained	NULL
by	NULL
the	NULL
consensus	NULL
sequence	NULL
of	NULL
ZII	NULL
differing	NULL
by	NULL
1	NULL
nucle-	NULL
#	NULL
&	NULL
i	NULL
€	NULL
L	NULL
L	NULL
go	NULL
$	NULL
o	NULL
f	NULL
i	NULL
if	NULL
i	NULL
$	NULL
:	NULL
3	NULL
=	NULL
I	NULL
=	NULL
E	NULL
[	NULL
=	NULL
)	NULL
[	NULL
=	NULL
)	NULL
Competition	NULL
=	NULL
#	NULL
0	NULL
t	NULL
0	NULL
#	NULL
of	NULL
+	NULL
of	NULL
+	NULL
+	NULL
+	NULL
+	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Noninducible	NULL
,	NULL
constitutively	NULL
expressed	NULL
nuclear	NULL
proteins	NULL
bind	NULL
AP-1/	NULL
CRE	NULL
of	NULL
ZII	NULL
.	NULL

Nuclear	NULL
extracts	NULL
(	NULL
2	NULL
mg	NULL
)	NULL
from	NULL
mock-infected	NULL
,	NULL
HHV-6-infected	NULL
,	NULL
or	NULL
TPA-treated	NULL
Jurkat	NULL
cells	NULL
,	NULL
obtained	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
,	NULL
were	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
15	NULL
min	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
+	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
of	NULL
unlabelled	NULL
ZII	NULL
oligonucleotides	NULL
(	NULL
40	NULL
ng	NULL
)	NULL
,	NULL
after	NULL
which	NULL
0.2	NULL
ng	NULL
of	NULL
*°P-end-labelled	NULL
ZII	NULL
oligonucleotides	NULL
was	NULL
added	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Samples	NULL
were	NULL
loaded	NULL
on	NULL
5	NULL
%	NULL
nondenaturing	NULL
Tris-glycine-EDTA	NULL
polyacrylamide	NULL
gels	NULL
and	NULL
migrated	NULL
at	NULL
60	NULL
mA	NULL
,	NULL
after	NULL
which	NULL
the	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
exposed	NULL
to	NULL
films	NULL
.	NULL

1788	NULL
FLAMAND	NULL
AND	NULL
MENEZES	NULL
Probe	NULL
:	NULL
ZI	NULL
CRE	NULL
AP-1	NULL
L	NULL
%	NULL
y	NULL
L0	NULL
7	NULL
T	NULL
<	NULL
Competition	NULL
__|	NULL
N	NULL
5	NULL
z	NULL
1	NULL
§	NULL
5	NULL
<	NULL
g	NULL
E	NULL
Lane	NULL
1	NULL
203	NULL
i	NULL
5	NULL
6	NULL
_	NULL
7	NULL
8	NULL
92	NULL
10	NULL
¥	NULL
_..	NULL
-	NULL
Ames	NULL
(	NULL
#	NULL
#	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Competition	NULL
by	NULL
CRE	NULL
but	NULL
not	NULL
AP-1	NULL
oligonucleotides	NULL
for	NULL
protein	NULL
binding	NULL
to	NULL
ZIL	NULL
Nuclear	NULL
extracts	NULL
(	NULL
2	NULL
mg	NULL
)	NULL
from	NULL
4-h	NULL
HHV-6-infected	NULL
Jurkat	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
40	NULL
ng	NULL
of	NULL
unlabelled	NULL
ZII	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
6	NULL
)	NULL
,	NULL
CRE	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
7	NULL
)	NULL
,	NULL
or	NULL
AP-1	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
8	NULL
)	NULL
oligonucleotides	NULL
for	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
,	NULL
after	NULL
which	NULL
0.2	NULL
ng	NULL
of	NULL
P-labelled	NULL
ZII	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
4	NULL
)	NULL
or	NULL
CRE	NULL
oligonucleotides	NULL
(	NULL
lanes	NULL
5	NULL
to	NULL
8	NULL
)	NULL
was	NULL
added	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Also	NULL
shown	NULL
is	NULL
the	NULL
binding	NULL
of	NULL
proteins	NULL
to	NULL
AP-1	NULL
oligonucleotides	NULL
(	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
.	NULL

Extracts	NULL
from	NULL
mock-infected	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
and	NULL
TPA-treated	NULL
(	NULL
lane	NULL
10	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
allowed	NULL
to	NULL
bind	NULL
to	NULL
0.2	NULL
ng	NULL
of	NULL
*°P-labelled	NULL
AP-1	NULL
oligonucleotides	NULL
before	NULL
electrophoresis	NULL
,	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

5.	NULL
otide	NULL
from	NULL
the	NULL
wild-type	NULL
CRE	NULL
sequence	NULL
.	NULL

Excess	NULL
AP-1	NULL
oligonucleotides	NULL
had	NULL
marginal	NULL
effects	NULL
on	NULL
protein	NULL
binding	NULL
to	NULL
CRE	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

Not	NULL
all	NULL
of	NULL
the	NULL
faster-migrating	NULL
complex	NULL
can	NULL
be	NULL
inhibited	NULL
with	NULL
cold	NULL
ZII	NULL
or	NULL
CRE	NULL
oligonucleotides	NULL
,	NULL
suggesting	NULL
that	NULL
factors	NULL
other	NULL
than	NULL
CREB-like	NULL
proteins	NULL
attach	NULL
to	NULL
this	NULL
sequence	NULL
.	NULL

Also	NULL
shown	NULL
is	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
from	NULL
mock-infected	NULL
and	NULL
4-h	NULL
TPA-treated	NULL
Jurkat	NULL
cells	NULL
to	NULL
AP-1	NULL
oligonucleotides	NULL
.	NULL

Binding	NULL
to	NULL
AP-1	NULL
is	NULL
increased	NULL
by	NULL
TPA	NULL
(	NULL
compare	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
,	NULL
and	NULL
the	NULL
migration	NULL
pattern	NULL
of	NULL
proteins	NULL
is	NULL
considerably	NULL
different	NULL
from	NULL
that	NULL
of	NULL
those	NULL
bound	NULL
to	NULL
ZII	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
and	NULL
CRE	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Proteins	NULL
bound	NULL
to	NULL
ZII	NULL
can	NULL
be	NULL
supershifted	NULL
with	NULL
anti-CREB	NULL
protein	NULL
serum	NULL
.	NULL

Evidence	NULL
obtained	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
suggests	NULL
that	NULL
proteins	NULL
bound	NULL
to	NULL
ZII	NULL
have	NULL
identical	NULL
electrophoretic	NULL
mobility	NULL
to	NULL
those	NULL
bound	NULL
to	NULL
CRE	NULL
and	NULL
that	NULL
their	NULL
binding	NULL
can	NULL
be	NULL
prevented	NULL
by	NULL
preincubation	NULL
with	NULL
CRE	NULL
oligonucleotides	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
complexes	NULL
bound	NULL
to	NULL
ZII	NULL
were	NULL
CREB	NULL
proteins	NULL
,	NULL
nuclear	NULL
extracts	NULL
from	NULL
HHV-6-infected	NULL
Jurkat	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
ZII	NULL
oligonucleotides	NULL
and	NULL
then	NULL
with	NULL
antibodies	NULL
against	NULL
c-fos	NULL
,	NULL
c-jun	NULL
,	NULL
and	NULL
CREB	NULL
protein	NULL
.	NULL

By	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
,	NULL
it	NULL
was	NULL
observed	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
that	NULL
antibodies	NULL
against	NULL
c-fos	NULL
or	NULL
c-jun	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
complexes	NULL
bound	NULL
to	NULL
ZII	NULL
(	NULL
compare	NULL
lane	NULL
1	NULL
with	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

However	NULL
,	NULL
incubation	NULL
of	NULL
extracts	NULL
with	NULL
anti-CREB	NULL
protein	NULL
serum	NULL
led	NULL
to	NULL
a	NULL
retardation	NULL
in	NULL
the	NULL
mobility	NULL
of	NULL
the	NULL
two	NULL
protein	NULL
complexes	NULL
(	NULL
supershift	NULL
)	NULL
bound	NULL
to	NULL
ZII	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
indicating	NULL
the	NULL
interaction	NULL
of	NULL
anti-CREB	NULL
protein	NULL
antibodies	NULL
with	NULL
proteins	NULL
bound	NULL
to	NULL
ZII	NULL
.	NULL

The	NULL
faster-migrating	NULL
complex	NULL
was	NULL
not	NULL
totally	NULL
supershifted	NULL
by	NULL
CREB	NULL
protein	NULL
antiserum	NULL
,	NULL
indicating	NULL
the	NULL
presence	NULL
of	NULL
nonimmunologically	NULL
reactive	NULL
proteins	NULL
bound	NULL
to	NULL
ZIL	NULL
.	NULL

J.	NULL
ViroL	NULL
.	NULL

Phosphorylated	NULL
CREB	NULL
protein	NULL
can	NULL
efficiently	NULL
activate	NULL
the	NULL
Zebra	NULL
promoter	NULL
.	NULL

The	NULL
identification	NULL
of	NULL
CREB	NULL
or	NULL
CREB-like	NULL
proteins	NULL
binding	NULL
Zp	NULL
through	NULL
its	NULL
ZII	NULL
domain	NULL
suggests	NULL
a	NULL
role	NULL
for	NULL
this	NULL
factor	NULL
in	NULL
Zebra	NULL
gene	NULL
activation	NULL
.	NULL

CREB	NULL
proteins	NULL
are	NULL
members	NULL
of	NULL
the	NULL
cAMP-responsive	NULL
factor	NULL
family	NULL
and	NULL
rely	NULL
upon	NULL
phosphorylation	NULL
by	NULL
various	NULL
kinases	NULL
,	NULL
including	NULL
PKA	NULL
,	NULL
Ca	NULL
*	NULL
-calmodulin-dependent	NULL
kinase	NULL
,	NULL
and	NULL
PKC	NULL
(	NULL
21	NULL
,	NULL
40	NULL
,	NULL
50	NULL
,	NULL
53	NULL
)	NULL
for	NULL
transcriptional	NULL
activity	NULL
.	NULL

We	NULL
next	NULL
determined	NULL
the	NULL
effect	NULL
of	NULL
forskolin	NULL
,	NULL
a	NULL
known	NULL
adenylate	NULL
cyclase	NULL
activator	NULL
,	NULL
on	NULL
Zp	NULL
activation	NULL
.	NULL

By	NULL
itself	NULL
,	NULL
forskolin	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
-86Zpcat-transfected	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
)	NULL
.	NULL

However	NULL
,	NULL
when	NULL
forskolin	NULL
was	NULL
added	NULL
together	NULL
with	NULL
HHV-6	NULL
,	NULL
a	NULL
significant	NULL
increase	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
in	NULL
activity	NULL
was	NULL
observed	NULL
when	NULL
compared	NULL
with	NULL
cultures	NULL
treated	NULL
with	NULL
HHV-6	NULL
only	NULL
.	NULL

To	NULL
further	NULL
demonstrate	NULL
that	NULL
CREB	NULL
protein	NULL
can	NULL
in	NULL
fact	NULL
transactivate	NULL
Zp	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
-86Zplue	NULL
along	NULL
with	NULL
vectors	NULL
expressing	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
PKA	NULL
and	NULL
GALA4-CREB	NULL
fusion	NULL
protein	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8B	NULL
,	NULL
transfection	NULL
of	NULL
either	NULL
CREB	NULL
or	NULL
PKA	NULL
expression	NULL
vectors	NULL
alone	NULL
did	NULL
not	NULL
result	NULL
in	NULL
significant	NULL
activation	NULL
of	NULL
-86Zpluc	NULL
.	NULL

However	NULL
,	NULL
when	NULL
the	NULL
two	NULL
expression	NULL
vectors	NULL
were	NULL
combined	NULL
,	NULL
a	NULL
highly	NULL
significant	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
increase	NULL
in	NULL
luciferase	NULL
activity	NULL
was	NULL
registered	NULL
,	NULL
suggesting	NULL
that	NULL
only	NULL
phosphorylated	NULL
CREB	NULL
protein	NULL
can	NULL
efficiently	NULL
activate	NULL
Zp	NULL
.	NULL

No	NULL
effect	NULL
on	NULL
-65Zplue	NULL
was	NULL
observed	NULL
under	NULL
the	NULL
same	NULL
conditions	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

DISCUSSION	NULL
Herpesviruses	NULL
have	NULL
a	NULL
complex	NULL
gene	NULL
regulation	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
EBV	NULL
,	NULL
viral	NULL
expression	NULL
during	NULL
latency	NULL
is	NULL
limited	NULL
to	NULL
nine	NULL
genes	NULL
.	NULL

During	NULL
the	NULL
replicative	NULL
cycle	NULL
,	NULL
genes	NULL
are	NULL
expressed	NULL
in	NULL
a	NULL
temporal	NULL
fashion	NULL
,	NULL
with	NULL
the	NULL
immediate-early	NULL
genes	NULL
transcribed	NULL
first	NULL
.	NULL

These	NULL
gene	NULL
products	NULL
then	NULL
activate	NULL
early	NULL
genes	NULL
,	NULL
which	NULL
in	NULL
turn	NULL
stimulate	NULL
transcription	NULL
of	NULL
the	NULL
late	NULL
genes	NULL
,	NULL
completing	NULL
the	NULL
cycle	NULL
.	NULL

One	NULL
such	NULL
immediate-early	NULL
transactivator	NULL
is	NULL
Zebra	NULL
,	NULL
encoded	NULL
by	NULL
the	NULL
BZLF1	NULL
gene	NULL
of	NULL
EBV	NULL
.	NULL

Zebra	NULL
expression	NULL
in	NULL
latently	NULL
infected	NULL
cells	NULL
is	NULL
presumably	NULL
silenced	NULL
by	NULL
negative	NULL
cis-acting	NULL
regulatory	NULL
elements	NULL
(	NULL
-386	NULL
to	NULL
-434	NULL
)	NULL
found	NULL
within	NULL
Zp	NULL
(	NULL
43	NULL
)	NULL
.	NULL

However	NULL
,	NULL
upon	NULL
cell	NULL
stimulation	NULL
with	NULL
TPA	NULL
or	NULL
anti-IgG	NULL
,	NULL
Zebra	NULL
gene	NULL
expression	NULL
is	NULL
turned	NULL
on	NULL
and	NULL
the	NULL
replicative	NULL
cycle	NULL
of	NULL
EBV	NULL
is	NULL
initiated	NULL
(	NULL
6	NULL
,	NULL
11	NULL
,	NULL
51	NULL
)	NULL
.	NULL

Regions	NULL
of	NULL
Zp	NULL
responsive	NULL
to	NULL
TPA	NULL
and	NULL
anti-Ig	NULL
activation	NULL
have	NULL
been	NULL
identified	NULL
(	NULL
18	NULL
,	NULL
49	NULL
)	NULL
.	NULL

However	NULL
,	NULL
Zp	NULL
is	NULL
minimally	NULL
activated	NULL
by	NULL
TPA	NULL
in	NULL
non-EBV-carrying	NULL
cell	NULL
lines	NULL
,	NULL
suggesting	NULL
that	NULL
TPA-responsive	NULL
elements	NULL
may	NULL
not	NULL
be	NULL
sufficient	NULL
to	NULL
&	NULL
mags	NULL
to	NULL
b	NULL
&	NULL
Antibodies	NULL
to	NULL
:	NULL
Io	NULL
ho	NULL
a	NULL
O	NULL
-t-	NULL
Supershift	NULL
Shift	NULL
-im	NULL
n	NULL
-a-	NULL
Supershift	NULL
Wn	NULL
i	NULL
ts	NULL
:	NULL
s	NULL
:	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Proteins	NULL
bound	NULL
to	NULL
ZII	NULL
can	NULL
be	NULL
supershifted	NULL
with	NULL
anti-CREB	NULL
protein	NULL
serum	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
4-h	NULL
HHV-6-infected	NULL
Jurkat	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
*°P-labelled	NULL
ZII	NULL
oligonucleotides	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Antibodies	NULL
against	NULL
c-Fos	NULL
,	NULL
c-Jun	NULL
,	NULL
or	NULL
CREB	NULL
protein	NULL
were	NULL
added	NULL
to	NULL
the	NULL
mixtures	NULL
,	NULL
and	NULL
incubation	NULL
was	NULL
prolonged	NULL
for	NULL
an	NULL
additional	NULL
30	NULL
min	NULL
.	NULL

Samples	NULL
were	NULL
electropho-resed	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

5.	NULL
voL	NULL
.	NULL

70	NULL
,	NULL
1996	NULL
HHV-6	NULL
+	NULL
Forskolin	NULL
HHV-6	NULL
Forskolin	NULL
Mock	NULL
u	NULL
T	NULL
T	NULL
t	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
70	NULL
B	NULL
Fold	NULL
activation	NULL
CREB	NULL
+	NULL
PKA	NULL
PKA	NULL
Creb	NULL
Puc18	NULL
t	NULL
T-	NULL
t	NULL
t	NULL
0	NULL
200	NULL
400	NULL
-	NULL
600	NULL
t	NULL
J	NULL
800	NULL
1000	NULL
1200	NULL
1400	NULL
Relative	NULL
Luciferase	NULL
Unit	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

Enhancement	NULL
of	NULL
Zp	NULL
activation	NULL
by	NULL
forskolin	NULL
and	NULL
phosphorylated	NULL
CREB	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
-86Zpcat	NULL
reporter	NULL
construct	NULL
and	NULL
infected	NULL
with	NULL
HHV-6	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
forskolin	NULL
was	NULL
then	NULL
determined	NULL
by	NULL
adding	NULL
10	NULL
M	NULL
of	NULL
this	NULL
chemical	NULL
to	NULL
both	NULL
uninfected	NULL
and	NULL
infected	NULL
cultures	NULL
.	NULL

The	NULL
enhanced	NULL
(	NULL
x	NULL
,	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
CAT	NULL
activity	NULL
shown	NULL
was	NULL
determined	NULL
48	NULL
h	NULL
postinfection	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
Zplue	NULL
reporter	NULL
vector	NULL
(	NULL
2	NULL
mg	NULL
)	NULL
with	NULL
or	NULL
without	NULL
CREB	NULL
(	NULL
1	NULL
pg	NULL
)	NULL
and	NULL
PKA	NULL
(	NULL
1	NULL
mg	NULL
)	NULL
expression	NULL
vectors	NULL
.	NULL

DNA	NULL
input	NULL
was	NULL
normalized	NULL
with	NULL
puc18	NULL
DNA	NULL
.	NULL

At	NULL
72	NULL
h	NULL
posttransfection	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
tested	NULL
for	NULL
luciferase	NULL
activity	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Results	NULL
are	NULL
presented	NULL
as	NULL
mean	NULL
+	NULL
standard	NULL
deviation	NULL
of	NULL
relative	NULL
luciferase	NULL
units	NULL
derived	NULL
from	NULL
three	NULL
independent	NULL
transfections	NULL
(	NULL
*	NULL
,	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
.	NULL

fully	NULL
activate	NULL
Zp	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EBV	NULL
proteins	NULL
(	NULL
15a	NULL
,	NULL
49	NULL
)	NULL
.	NULL

Having	NULL
observed	NULL
that	NULL
HHV-6	NULL
can	NULL
efficiently	NULL
activate	NULL
Zp	NULL
in	NULL
both	NULL
EBV-carrying	NULL
B	NULL
cells	NULL
and	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
identify	NULL
other	NULL
responsive	NULL
elements	NULL
participating	NULL
in	NULL
Zp	NULL
activation	NULL
.	NULL

Promoter	NULL
elements	NULL
responding	NULL
to	NULL
cAMP	NULL
are	NULL
referred	NULL
to	NULL
as	NULL
CRE	NULL
(	NULL
cAMP-responsive	NULL
elements	NULL
)	NULL
(	NULL
10	NULL
,	NULL
13	NULL
,	NULL
47	NULL
)	NULL
.	NULL

Factors	NULL
binding	NULL
to	NULL
CRE	NULL
sequences	NULL
(	NULL
TGACGTCA	NULL
)	NULL
such	NULL
as	NULL
CREB	NULL
protein	NULL
or	NULL
CRE-modulating	NULL
(	NULL
CREM	NULL
)	NULL
protein	NULL
belong	NULL
to	NULL
the	NULL
leucine	NULL
zipper	NULL
(	NULL
b-Zip	NULL
)	NULL
class	NULL
of	NULL
proteins	NULL
(	NULL
20	NULL
,	NULL
22	NULL
,	NULL
23	NULL
,	NULL
26	NULL
)	NULL
.	NULL

CREB	NULL
and	NULL
CREM	NULL
proteins	NULL
share	NULL
homologies	NULL
with	NULL
b-Zip	NULL
proteins	NULL
capable	NULL
of	NULL
binding	NULL
to	NULL
TPA-responsive	NULL
elements	NULL
such	NULL
as	NULL
the	NULL
AP-1	NULL
transcription	NULL
complex	NULL
,	NULL
composed	NULL
of	NULL
homodimerized	NULL
Jun	NULL
or	NULL
of	NULL
the	NULL
Fos-Jun	NULL
heterodimer	NULL
(	NULL
4	NULL
,	NULL
8	NULL
,	NULL
32	NULL
,	NULL
48	NULL
)	NULL
.	NULL

AP-1	NULL
is	NULL
induced	NULL
by	NULL
TPA	NULL
stimulation	NULL
and	NULL
regulates	NULL
the	NULL
expression	NULL
of	NULL
many	NULL
genes	NULL
having	NULL
TPA-responsive	NULL
elements	NULL
in	NULL
their	NULL
promoter	NULL
(	NULL
3	NULL
,	NULL
34	NULL
)	NULL
.	NULL

By	NULL
con-trast	NULL
,	NULL
proteins	NULL
binding	NULL
to	NULL
CRE	NULL
are	NULL
constitutively	NULL
expressed	NULL
in	NULL
cells	NULL
and	NULL
can	NULL
exert	NULL
both	NULL
silencing	NULL
and	NULL
stimulating	NULL
effects	NULL
.	NULL

CREM	NULL
protein	NULL
prevents	NULL
gene	NULL
activation	NULL
by	NULL
occupying	NULL
CRE	NULL
sites	NULL
either	NULL
as	NULL
a	NULL
homodimer	NULL
or	NULL
as	NULL
a	NULL
CREM-CREB	NULL
protein	NULL
heterodimer	NULL
(	NULL
20	NULL
)	NULL
.	NULL

It	NULL
is	NULL
thought	NULL
that	NULL
upon	NULL
cAMP	NULL
induction	NULL
,	NULL
phosphorylated	NULL
CREB	NULL
dimers	NULL
override	NULL
the	NULL
negative	NULL
CREM	NULL
protein	NULL
influence	NULL
and	NULL
promoter	NULL
gene	NULL
transcription	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
EBV	NULL
ZEBRA	NULL
PROMOTER	NULL
ACTIVATION	NULL
BY	NULL
HHV-6	NULL
1789	NULL
EBV	NULL
Zp	NULL
contains	NULL
a	NULL
DNA	NULL
sequence	NULL
(	NULL
TGACATCA	NULL
)	NULL
related	NULL
to	NULL
both	NULL
AP-1	NULL
and	NULL
CRE	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Such	NULL
sequence	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
AP-1	NULL
(	NULL
Jun	NULL
plus	NULL
Fos	NULL
)	NULL
,	NULL
but	NULL
transactivation	NULL
of	NULL
Zp	NULL
by	NULL
Jun	NULL
in	NULL
the	NULL
Ramos	NULL
B-cell	NULL
line	NULL
was	NULL
not	NULL
observed	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
a	NULL
sequence	NULL
identical	NULL
to	NULL
the	NULL
AP-1/CRE	NULL
site	NULL
found	NULL
in	NULL
Zp	NULL
is	NULL
also	NULL
present	NULL
in	NULL
the	NULL
c-jun	NULL
promoter	NULL
(	NULL
7	NULL
)	NULL
.	NULL

This	NULL
sequence	NULL
was	NULL
shown	NULL
to	NULL
bind	NULL
both	NULL
CREM	NULL
and	NULL
CREB	NULL
proteins	NULL
,	NULL
causing	NULL
downregulation	NULL
of	NULL
c-jun	NULL
gene	NULL
expression	NULL
.	NULL

Such	NULL
inhibition	NULL
can	NULL
be	NULL
reversed	NULL
by	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
protein	NULL
by	NULL
PKA	NULL
(	NULL
31	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
work	NULL
,	NULL
we	NULL
provide	NULL
evidence	NULL
that	NULL
superinfection	NULL
of	NULL
the	NULL
EBV	NULL
genome-positive	NULL
Raji	NULL
cell	NULL
line	NULL
by	NULL
HHV-6	NULL
results	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
Zebra	NULL
mRNA	NULL
.	NULL

Moreover	NULL
,	NULL
our	NULL
results	NULL
indicate	NULL
that	NULL
HHV-6	NULL
can	NULL
activate	NULL
Zp	NULL
independently	NULL
of	NULL
any	NULL
EBV-encoded	NULL
proteins	NULL
.	NULL

Using	NULL
5'-deleted	NULL
Zp	NULL
constructs	NULL
together	NULL
with	NULL
mu-tagenized	NULL
Zp	NULL
,	NULL
we	NULL
have	NULL
identified	NULL
a	NULL
region	NULL
between	NULL
-86	NULL
and	NULL
-65	NULL
of	NULL
Zp	NULL
essential	NULL
for	NULL
activation	NULL
by	NULL
HHV-6	NULL
.	NULL

This	NULL
region	NULL
contains	NULL
the	NULL
consensus	NULL
AP-1/CRE	NULL
sequences	NULL
mentioned	NULL
above	NULL
.	NULL

We	NULL
show	NULL
that	NULL
CREB	NULL
or	NULL
CREB-like	NULL
proteins	NULL
are	NULL
involved	NULL
in	NULL
Zp	NULL
activation	NULL
following	NULL
HHV-6	NULL
infection	NULL
,	NULL
since	NULL
(	NULL
i	NULL
)	NULL
mutation	NULL
of	NULL
the	NULL
CRE	NULL
site	NULL
within	NULL
the	NULL
ZII	NULL
domain	NULL
of	NULL
Zp	NULL
abolished	NULL
responsiveness	NULL
to	NULL
HHV-6	NULL
infection	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
noninducible	NULL
,	NULL
constitutively	NULL
expressed	NULL
factors	NULL
were	NULL
found	NULL
to	NULL
bind	NULL
the	NULL
putative	NULL
CRE	NULL
site	NULL
found	NULL
in	NULL
ZII	NULL
,	NULL
in	NULL
agreement	NULL
with	NULL
intrinsic	NULL
biological	NULL
properties	NULL
of	NULL
CREB	NULL
proteins	NULL
;	NULL
(	NULL
iii	NULL
)	NULL
protein	NULL
binding	NULL
to	NULL
the	NULL
putative	NULL
CRE	NULL
site	NULL
of	NULL
ZII	NULL
was	NULL
prevented	NULL
by	NULL
oligonucleotides	NULL
containing	NULL
wild-type	NULL
CRE	NULL
consensus	NULL
sequence	NULL
;	NULL
(	NULL
iv	NULL
)	NULL
proteins	NULL
,	NULL
whether	NULL
bound	NULL
to	NULL
oligonucleotides	NULL
with	NULL
wild-type	NULL
CRE	NULL
or	NULL
ZII-CRE	NULL
,	NULL
have	NULL
the	NULL
same	NULL
electrophoretic	NULL
mobility	NULL
;	NULL
(	NULL
v	NULL
)	NULL
proteins	NULL
bound	NULL
to	NULL
ZII-CRE	NULL
can	NULL
be	NULL
supershifted	NULL
by	NULL
anti-CREB	NULL
protein	NULL
antiserum	NULL
;	NULL
and	NULL
(	NULL
vi	NULL
)	NULL
cotransfection	NULL
of	NULL
vectors	NULL
driving	NULL
the	NULL
expression	NULL
of	NULL
CREB	NULL
protein	NULL
and	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
PKA	NULL
was	NULL
able	NULL
to	NULL
activate	NULL
Zp	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
activation	NULL
of	NULL
Zp	NULL
by	NULL
HHV-6	NULL
was	NULL
enhanced	NULL
by	NULL
forskolin	NULL
,	NULL
which	NULL
indirectly	NULL
activates	NULL
PKA	NULL
through	NULL
an	NULL
increase	NULL
in	NULL
intracellular	NULL
cAMP	NULL
levels	NULL
.	NULL

Evidence	NULL
against	NULL
the	NULL
involvement	NULL
of	NULL
AP-1	NULL
in	NULL
Zp	NULL
activation	NULL
by	NULL
HHV-6	NULL
includes	NULL
the	NULL
following	NULL
:	NULL
(	NULL
i	NULL
)	NULL
it	NULL
is	NULL
not	NULL
possible	NULL
to	NULL
supershift	NULL
proteins	NULL
bound	NULL
to	NULL
ZII	NULL
by	NULL
antibodies	NULL
against	NULL
c-fos	NULL
and	NULL
c-jun	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
protein	NULL
complexes	NULL
bound	NULL
to	NULL
ZII	NULL
have	NULL
different	NULL
electrophoretic	NULL
mobility	NULL
from	NULL
those	NULL
bound	NULL
to	NULL
oligonucleotides	NULL
with	NULL
AP-1	NULL
sequence	NULL
;	NULL
(	NULL
iii	NULL
)	NULL
AP-1	NULL
oligonucleotides	NULL
can	NULL
not	NULL
compete	NULL
efficiently	NULL
with	NULL
ZII	NULL
for	NULL
binding	NULL
of	NULL
proteins	NULL
;	NULL
and	NULL
(	NULL
iv	NULL
)	NULL
TPA	NULL
treatment	NULL
of	NULL
cells	NULL
does	NULL
not	NULL
modulate	NULL
the	NULL
binding	NULL
of	NULL
proteins	NULL
to	NULL
ZII	NULL
but	NULL
does	NULL
increase	NULL
AP-1	NULL
binding	NULL
.	NULL

To	NULL
our	NULL
knowledge	NULL
this	NULL
is	NULL
the	NULL
first	NULL
report	NULL
of	NULL
a	NULL
CRE	NULL
sequence-dependent	NULL
activation	NULL
of	NULL
BZLF1	NULL
promoter	NULL
of	NULL
EBV	NULL
.	NULL

Previous	NULL
reports	NULL
have	NULL
identified	NULL
TRE	NULL
sequence	NULL
involvement	NULL
in	NULL
EBV	NULL
reactivation	NULL
following	NULL
TPA	NULL
or	NULL
anti-IgG	NULL
stimulation	NULL
of	NULL
cells	NULL
(	NULL
33	NULL
,	NULL
41	NULL
)	NULL
.	NULL

Our	NULL
approach	NULL
has	NULL
the	NULL
advantage	NULL
of	NULL
enabling	NULL
us	NULL
to	NULL
study	NULL
the	NULL
activation	NULL
of	NULL
Zebra	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EBV	NULL
proteins	NULL
which	NULL
might	NULL
influence	NULL
this	NULL
process	NULL
.	NULL

Utilization	NULL
of	NULL
cellular	NULL
transcription	NULL
factors	NULL
by	NULL
viruses	NULL
for	NULL
regulation	NULL
of	NULL
promoter	NULL
activity	NULL
is	NULL
common	NULL
.	NULL

The	NULL
most	NULL
thoroughly	NULL
studied	NULL
of	NULL
all	NULL
recently	NULL
isolated	NULL
viruses	NULL
,	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
,	NULL
is	NULL
known	NULL
to	NULL
make	NULL
use	NULL
of	NULL
factors	NULL
such	NULL
as	NULL
NF-	NULL
«	NULL
b	NULL
(	NULL
24	NULL
,	NULL
44	NULL
)	NULL
and	NULL
SP1	NULL
(	NULL
29	NULL
)	NULL
to	NULL
facilitate	NULL
its	NULL
gene	NULL
transcription	NULL
.	NULL

Another	NULL
retrovirus	NULL
,	NULL
the	NULL
bovine	NULL
leukemia	NULL
virus	NULL
,	NULL
utilizes	NULL
CREB	NULL
proteins	NULL
in	NULL
Tax-mediated	NULL
long	NULL
terminal	NULL
repeat	NULL
transactivation	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
adenovirus	NULL
E1A	NULL
oncoprotein	NULL
seems	NULL
to	NULL
exert	NULL
its	NULL
transactivating	NULL
effect	NULL
in	NULL
conjunction	NULL
with	NULL
CREB-related	NULL
proteins	NULL
(	NULL
25	NULL
,	NULL
28	NULL
,	NULL
37	NULL
,	NULL
47	NULL
)	NULL
.	NULL

The	NULL
utilization	NULL
of	NULL
CREB	NULL
proteins	NULL
by	NULL
HHV-6	NULL
to	NULL
promote	NULL
gene	NULL
transcription	NULL
may	NULL
represent	NULL
an	NULL
evolutionary	NULL
adaptation	NULL
of	NULL
this	NULL
virus	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
an	NULL
AP-1	NULL
site	NULL
capable	NULL
of	NULL
binding	NULL
both	NULL
CREB	NULL
protein	NULL
and	NULL
AP-1	NULL
transcriptional	NULL
complexes	NULL
is	NULL
found	NULL
upstream	NULL
of	NULL
the	NULL
putative	NULL
immediate-early	NULL
gene	NULL
locus	NULL
of	NULL
HHV-6	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
it	NULL
was	NULL
recently	NULL
shown	NULL
that	NULL
the	NULL
HHV-6	NULL
DNA	NULL
polymerase	NULL
promoter	NULL
can	NULL
be	NULL
transactivated	NULL
after	NULL
infection	NULL
by	NULL
HHV-6	NULL
1790	NULL
FLAMAND	NULL
AND	NULL
MENEZES	NULL
through	NULL
a	NULL
CRE	NULL
consensus	NULL
sequence	NULL
(	NULL
2	NULL
)	NULL
.	NULL

CREB	NULL
protein	NULL
activation	NULL
following	NULL
infection	NULL
by	NULL
HHV-6	NULL
could	NULL
therefore	NULL
lead	NULL
to	NULL
enhanced	NULL
transcription	NULL
of	NULL
viral	NULL
genes	NULL
,	NULL
enabling	NULL
a	NULL
more	NULL
efficient	NULL
and	NULL
rapid	NULL
triggering	NULL
of	NULL
events	NULL
during	NULL
initiation	NULL
of	NULL
infection	NULL
.	NULL

We	NULL
are	NULL
currently	NULL
working	NULL
at	NULL
identifying	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
HHV-6	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
involved	NULL
in	NULL
CREB	NULL
protein	NULL
activation	NULL
.	NULL

It	NULL
is	NULL
noteworthy	NULL
,	NULL
however	NULL
,	NULL
that	NULL
seven	NULL
HHV-6	NULL
genomic	NULL
segments	NULL
which	NULL
were	NULL
known	NULL
to	NULL
transactivate	NULL
various	NULL
heterologous	NULL
promoters	NULL
and	NULL
some	NULL
of	NULL
which	NULL
encoded	NULL
immediate-early	NULL
protein	NULL
,	NULL
were	NULL
tested	NULL
during	NULL
this	NULL
study	NULL
and	NULL
were	NULL
found	NULL
to	NULL
be	NULL
ineffective	NULL
in	NULL
this	NULL
activation	NULL
.	NULL

On	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
present	NULL
findings	NULL
,	NULL
we	NULL
hypothesize	NULL
that	NULL
CREB/CREM	NULL
protein	NULL
occupancy	NULL
of	NULL
the	NULL
CRE	NULL
site	NULL
within	NULL
Zp	NULL
of	NULL
EBV	NULL
causes	NULL
silencing	NULL
of	NULL
the	NULL
BZLF1	NULL
gene	NULL
and	NULL
favors	NULL
a	NULL
latent	NULL
EBV	NULL
infection	NULL
.	NULL

Upon	NULL
infection	NULL
of	NULL
B	NULL
lymphocytes	NULL
by	NULL
HHV-6	NULL
,	NULL
a	NULL
virus-encoded	NULL
product	NULL
leads	NULL
to	NULL
CREB	NULL
protein	NULL
phosphoryla-tion	NULL
,	NULL
activation	NULL
of	NULL
Zp	NULL
,	NULL
and	NULL
transcription	NULL
of	NULL
the	NULL
gene	NULL
.	NULL

Zebra	NULL
protein	NULL
then	NULL
transactivates	NULL
various	NULL
EBV	NULL
promoters	NULL
,	NULL
initiating	NULL
the	NULL
cascade	NULL
of	NULL
events	NULL
leading	NULL
to	NULL
EBV	NULL
reactivation	NULL
.	NULL

Release	NULL
of	NULL
infectious	NULL
EBV	NULL
particles	NULL
can	NULL
lead	NULL
to	NULL
an	NULL
increase	NULL
in	NULL
virus	NULL
load	NULL
and	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
number	NULL
of	NULL
EBV-infected	NULL
B	NULL
lymphocytes	NULL
,	NULL
which	NULL
favor	NULL
the	NULL
development	NULL
on	NULL
EBV-related	NULL
diseases	NULL
such	NULL
as	NULL
B-cell	NULL
lymphoproliferation	NULL
.	NULL

In	NULL
immunodeficient	NULL
individuals	NULL
,	NULL
a	NULL
correlation	NULL
exists	NULL
between	NULL
the	NULL
degree	NULL
of	NULL
EBV	NULL
reactivation	NULL
and	NULL
the	NULL
incidence	NULL
of	NULL
EBV-related	NULL
lymphomas	NULL
.	NULL

Infection	NULL
by	NULL
,	NULL
or	NULL
reactivation	NULL
of	NULL
,	NULL
HHV-6	NULL
in	NULL
immunocompromised	NULL
hosts	NULL
may	NULL
therefore	NULL
contribute	NULL
dually	NULL
to	NULL
pathogenesis	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
through	NULL
HHV-6-associated	NULL
pathologies	NULL
and	NULL
through	NULL
reactivation	NULL
of	NULL
EBV	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
are	NULL
extremely	NULL
grateful	NULL
to	NULL
E.	NULL
K.	NULL
Flemington	NULL
for	NULL
kindly	NULL
supplying	NULL
Zebra-cat	NULL
constructs	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
J.	NULL
F.	NULL
Habener	NULL
for	NULL
anti-CREB	NULL
serum	NULL
;	NULL
R.	NULL
A.	NULL
Maurer	NULL
for	NULL
GALA-CREB	NULL
expression	NULL
vector	NULL
;	NULL
S.	NULL
McKnight	NULL
for	NULL
PKA	NULL
expression	NULL
vector	NULL
;	NULL
and	NULL
N.	NULL
Balachandran	NULL
,	NULL
L.	NULL
S.	NULL
Young	NULL
,	NULL
and	NULL
M.	NULL
Rowe	NULL
for	NULL
monoclonal	NULL
antibodies	NULL
.	NULL

Louis	NULL
Flamand	NULL
received	NULL
a	NULL
studentship	NULL
from	NULL
the	NULL
Medical	NULL
Research	NULL
Council	NULL
of	NULL
Canada	NULL
(	NULL
MRCC	NULL
)	NULL
.	NULL

This	NULL
research	NULL
was	NULL
supported	NULL
by	NULL
MRCC	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Ablashi	NULL
,	NULL
D.	NULL
V.	NULL
,	NULL
P.	NULL
Lusso	NULL
,	NULL
C.	NULL
L	NULL
,	NULL
Hung	NULL
,	NULL
S.	NULL
Z.	NULL
Salahuddin	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
T.	NULL
Liana	NULL
,	NULL
B.	NULL
Kramarsky	NULL
,	NULL
P.	NULL
Biberfield	NULL
,	NULL
P.	NULL
D.	NULL
Markham	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1988	NULL
.	NULL

Utilization	NULL
of	NULL
human	NULL
hematopoictic	NULL
cell	NULL
lines	NULL
for	NULL
the	NULL
propagation	NULL
and	NULL
characterization	NULL
of	NULL
HBLV	NULL
(	NULL
human	NULL
herpesvirus	NULL
6	NULL
)	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
42:787-791	NULL
.	NULL

2	NULL
.	NULL

Agulnick	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
J.	NULL
R.	NULL
Thompson	NULL
,	NULL
and	NULL
R.	NULL
P.	NULL
Riccardi	NULL
.	NULL

1994	NULL
.	NULL

An	NULL
ATF/CREB	NULL
site	NULL
is	NULL
the	NULL
major	NULL
regulatory	NULL
element	NULL
in	NULL
the	NULL
human	NULL
herpesvirus	NULL
6	NULL
DNA	NULL
polymerase	NULL
promoter	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:2970-2977	NULL
.	NULL

3	NULL
.	NULL

Angel	NULL
,	NULL
P.	NULL
,	NULL
M.	NULL
Imagawa	NULL
,	NULL
R.	NULL
Chiu	NULL
,	NULL
B.	NULL
Stein	NULL
,	NULL
R.	NULL
J.	NULL
Imbra	NULL
,	NULL
H.	NULL
J.	NULL
Rahmsdorf	NULL
,	NULL
C.	NULL
Jonat	NULL
,	NULL
P.	NULL
Herrlich	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1987	NULL
.	NULL

Phorbol	NULL
ester-inducible	NULL
genes	NULL
contain	NULL
a	NULL
common	NULL
cis	NULL
element	NULL
recognized	NULL
by	NULL
a	NULL
TPA-modulated	NULL
trans-acting	NULL
factor	NULL
.	NULL

Cell	NULL
49:729-739	NULL
.	NULL

4	NULL
.	NULL

Busch	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
and	NULL
P.	NULL
Sassone-Corsi	NULL
.	NULL

1990	NULL
.	NULL

Dimers	NULL
,	NULL
leucine	NULL
zippers	NULL
and	NULL
DNA	NULL
binding	NULL
domains	NULL
.	NULL

Trends	NULL
Genet	NULL
.	NULL

6:36-40	NULL
.	NULL

5	NULL
.	NULL

Chang	NULL
,	NULL
Y.	NULL
N.	NULL
,	NULL
D.	NULL
L.	NULL
Y.	NULL
Dong	NULL
,	NULL
G.	NULL
S.	NULL
Hayward	NULL
,	NULL
and	NULL
D.	NULL
Hayward	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
Zta	NULL
transactivator	NULL
:	NULL
a	NULL
member	NULL
of	NULL
the	NULL
bZip	NULL
family	NULL
with	NULL
unique	NULL
DNA-binding	NULL
specificity	NULL
and	NULL
a	NULL
dimerization	NULL
domain	NULL
that	NULL
lacks	NULL
the	NULL
characteristic	NULL
heptad	NULL
leucine	NULL
zipper	NULL
motif	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:3358-3369	NULL
.	NULL

6	NULL
.	NULL

Chevallier-Greco	NULL
,	NULL
A.	NULL
,	NULL
E.	NULL
Manet	NULL
,	NULL
P.	NULL
Charrier	NULL
,	NULL
C.	NULL
Mosnier	NULL
,	NULL
J.	NULL
Daillie	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1986	NULL
.	NULL

Both	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
-encoded	NULL
trans-acting	NULL
factor	NULL
EB1	NULL
and	NULL
EB2	NULL
,	NULL
are	NULL
required	NULL
to	NULL
activate	NULL
transcription	NULL
from	NULL
an	NULL
EBV	NULL
carly	NULL
promoter	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

5:3243-3249	NULL
.	NULL

7	NULL
.	NULL

Chiu	NULL
,	NULL
R.	NULL
,	NULL
P.	NULL
Angel	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1989	NULL
.	NULL

Jun-B	NULL
differs	NULL
in	NULL
its	NULL
biological	NULL
properties	NULL
from	NULL
,	NULL
and	NULL
is	NULL
a	NULL
negative	NULL
regulator	NULL
of	NULL
,	NULL
c-Jun	NULL
.	NULL

Cell	NULL
59:979-986	NULL
.	NULL

8	NULL
.	NULL

Chiu	NULL
,	NULL
R.	NULL
,	NULL
W.	NULL
J.	NULL
Boyle	NULL
,	NULL
J.	NULL
Meek	NULL
,	NULL
T.	NULL
Smeal	NULL
,	NULL
T.	NULL
Hunter	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
c-Fos	NULL
protein	NULL
interacts	NULL
with	NULL
c-Jun/AP-1	NULL
to	NULL
stimulate	NULL
transcription	NULL
of	NULL
AP-1	NULL
responsive	NULL
genes	NULL
.	NULL

Cell	NULL
54:541-552	NULL
.	NULL

9	NULL
.	NULL

Chomezynski	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
N.	NULL
Sacchi	NULL
.	NULL

1987	NULL
.	NULL

Single-step	NULL
method	NULL
of	NULL
RNA	NULL
isolation	NULL
by	NULL
acid	NULL
guanidium	NULL
thiocyanate-phenol-chloroform	NULL
extraction	NULL
.	NULL

Anal	NULL
.	NULL

Bio-chem	NULL
.	NULL

162:156-159	NULL
.	NULL

10	NULL
.	NULL

Comb	NULL
,	NULL
M.	NULL
,	NULL
N.	NULL
C.	NULL
Birnberg	NULL
,	NULL
A.	NULL
Seasholtz	NULL
,	NULL
E.	NULL
Herbert	NULL
,	NULL
and	NULL
H.	NULL
M.	NULL
Goodman	NULL
.	NULL

1986	NULL
.	NULL

A	NULL
cyclic	NULL
AMP	NULL
and	NULL
phorbol	NULL
ester-inducible	NULL
DNA	NULL
element	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
323:353-356	NULL
.	NULL

J.	NULL
ViroL	NULL
.	NULL

11	NULL
.	NULL

Countryman	NULL
,	NULL
J.	NULL
,	NULL
H.	NULL
Jenson	NULL
,	NULL
R.	NULL
Seibel	NULL
,	NULL
H.	NULL
Wolf	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
,	NULL
1987	NULL
.	NULL

Polymorphic	NULL
proteins	NULL
encoded	NULL
within	NULL
BZLF1	NULL
of	NULL
defective	NULL
and	NULL
standard	NULL
Epstein-Barr	NULL
viruses	NULL
disrupt	NULL
latency	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

61:3672-3679	NULL
.	NULL

12	NULL
.	NULL

Dambaugh	NULL
,	NULL
T.	NULL
,	NULL
K.	NULL
H	NULL
y	NULL
,	NULL
S.	NULL
F	NULL
Id	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1986	NULL
.	NULL

The	NULL
virus	NULL
genome	NULL
and	NULL
its	NULL
expression	NULL
in	NULL
latent	NULL
infection	NULL
,	NULL
p.	NULL
13-45	NULL
.	NULL

In	NULL
M.	NULL
A.	NULL
Epstein	NULL
and	NULL
B.	NULL
G.	NULL
Achong	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
The	NULL
Epstein-Barr	NULL
virus	NULL
:	NULL
recent	NULL
advances	NULL
.	NULL

W.	NULL
Heinemann	NULL
Medical	NULL
Books	NULL
,	NULL
London	NULL
.	NULL

13	NULL
.	NULL

Delegeane	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
L.	NULL
H.	NULL
Ferland	NULL
,	NULL
and	NULL
P.	NULL
L.	NULL
Mellon	NULL
.	NULL

1987	NULL
.	NULL

Tissue-specific	NULL
enhancer	NULL
of	NULL
the	NULL
human	NULL
glycoprotein	NULL
hormone	NULL
«	NULL
-subunit	NULL
gene	NULL
:	NULL
dependence	NULL
on	NULL
cyclic	NULL
AMP-inducible	NULL
elements	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7:3994-4002	NULL
.	NULL

14	NULL
.	NULL

Dignam	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
R.	NULL
M.	NULL
Lebovitz	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1983	NULL
.	NULL

Accurate	NULL
transcription	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11:1475-1489	NULL
.	NULL

15	NULL
.	NULL

Ensoli	NULL
,	NULL
B.	NULL
,	NULL
P.	NULL
Lusso	NULL
,	NULL
F.	NULL
Schatchter	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
J.	NULL
Rappaport	NULL
,	NULL
F.	NULL
Negro	NULL
,	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
and	NULL
F.	NULL
Wong-Staal	NULL
.	NULL

1989	NULL
.	NULL

Human	NULL
herpesvirus-6	NULL
increases	NULL
HIV-1	NULL
expression	NULL
in	NULL
co-infected	NULL
T	NULL
cells	NULL
via	NULL
the	NULL
nuclear	NULL
factor	NULL
binding	NULL
to	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:3019-3027	NULL
.	NULL

15a.Flamand	NULL
,	NULL
L	NULL
Unpublished	NULL
observations	NULL
.	NULL

16	NULL
.	NULL

Flamand	NULL
,	NULL
L.	NULL
,	NULL
I.	NULL
Stefanescu	NULL
,	NULL
D.	NULL
V.	NULL
Ablashi	NULL
,	NULL
and	NULL
J.	NULL
Menezes	NULL
.	NULL

1993	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
replicative	NULL
cycle	NULL
by	NULL
human	NULL
herpesvirus	NULL
6	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:6768-6777	NULL
.	NULL

17	NULL
.	NULL

Flemington	NULL
,	NULL
E.	NULL
K.	NULL
,	NULL
A.	NULL
E.	NULL
Goldfeld	NULL
,	NULL
and	NULL
S.	NULL
H.	NULL
Speck	NULL
.	NULL

1991	NULL
.	NULL

Efficient	NULL
transcription	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
immediate-early	NULL
BZLF1	NULL
and	NULL
BRLF1	NULL
genes	NULL
requires	NULL
protein	NULL
synthesis	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:7073-7077	NULL
.	NULL

18	NULL
.	NULL

Flemington	NULL
,	NULL
E.	NULL
K.	NULL
,	NULL
and	NULL
S.	NULL
H.	NULL
Speck	NULL
.	NULL

1990	NULL
.	NULL

Identification	NULL
of	NULL
phorbol	NULL
ester	NULL
response	NULL
elements	NULL
in	NULL
the	NULL
promoter	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
putative	NULL
lytic	NULL
switch	NULL
gene	NULL
BZLF1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:1217-1226	NULL
.	NULL

19	NULL
.	NULL

Flemington	NULL
,	NULL
E.	NULL
K.	NULL
,	NULL
and	NULL
S.	NULL
H.	NULL
Speck	NULL
.	NULL

1990	NULL
.	NULL

Autoregulation	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
putative	NULL
lytic	NULL
switch	NULL
gene	NULL
BZLF1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:1227-1232	NULL
.	NULL

20	NULL
.	NULL

Foulkes	NULL
,	NULL
N.	NULL
S.	NULL
,	NULL
E.	NULL
Borrelli	NULL
,	NULL
and	NULL
P.	NULL
Sassone-Corsi	NULL
.	NULL

1991	NULL
.	NULL

CREM	NULL
gene	NULL
:	NULL
use	NULL
of	NULL
alternative	NULL
DNA-binding	NULL
domains	NULL
generates	NULL
multiple	NULL
antagonists	NULL
of	NULL
cAMP-induced	NULL
transcription	NULL
.	NULL

Cell	NULL
64:739-749	NULL
.	NULL

21	NULL
.	NULL

Gonzales	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Montminy	NULL
.	NULL

1989	NULL
.	NULL

Cyclic	NULL
AMP	NULL
stimulates	NULL
stoma-tostatin	NULL
gene	NULL
transcription	NULL
by	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
at	NULL
serine	NULL
133	NULL
.	NULL

Cell	NULL
59:675-680	NULL
.	NULL

22	NULL
.	NULL

Habener	NULL
,	NULL
J	NULL
.	NULL

1990	NULL
.	NULL

Cyclic	NULL
AMP	NULL
response	NULL
element	NULL
binding	NULL
proteins	NULL
:	NULL
a	NULL
cornucopia	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

4:1087-1094	NULL
.	NULL

23	NULL
.	NULL

Hai	NULL
,	NULL
T.	NULL
,	NULL
F.	NULL
Lin	NULL
,	NULL
W.	NULL
J.	NULL
Coukos	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Green	NULL
.	NULL

1989	NULL
.	NULL

Transcription	NULL
factor	NULL
ATF	NULL
cDNA	NULL
clones	NULL
:	NULL
an	NULL
extensive	NULL
family	NULL
of	NULL
leucine	NULL
zipper	NULL
proteins	NULL
able	NULL
to	NULL
selectively	NULL
form	NULL
DNA-binding	NULL
heterodimers	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

3:2083-2090	NULL
.	NULL

24	NULL
.	NULL

Hammarskjold	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
and	NULL
M.	NULL
C.	NULL
Simurda	NULL
.	NULL

1992	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein	NULL
transactivates	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
through	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:6496-6501	NULL
.	NULL

25	NULL
.	NULL

Hardy	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
T.	NULL
Shenk	NULL
.	NULL

1988	NULL
.	NULL

Adenoviral	NULL
control	NULL
regions	NULL
activated	NULL
by	NULL
E1A	NULL
and	NULL
the	NULL
cAMP	NULL
responsive	NULL
element	NULL
bind	NULL
to	NULL
the	NULL
same	NULL
factor	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:4171-4175	NULL
.	NULL

26	NULL
.	NULL

Hoffler	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
T.	NULL
E.	NULL
Meyer	NULL
,	NULL
Y.	NULL
Yum	NULL
,	NULL
J.	NULL
L.	NULL
Jameson	NULL
,	NULL
and	NULL
J.	NULL
F.	NULL
Habener	NULL
.	NULL

1988	NULL
.	NULL

Cyclic	NULL
AMP-responsive	NULL
DNA-binding	NULL
protein	NULL
:	NULL
structure	NULL
based	NULL
on	NULL
a	NULL
cloned	NULL
placental	NULL
cDNA	NULL
.	NULL

Science	NULL
242:1430-1433	NULL
.	NULL

27	NULL
.	NULL

Horvat	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
C.	NULL
Wood	NULL
,	NULL
and	NULL
N.	NULL
Balachandran	NULL
.	NULL

1989	NULL
.	NULL

Transactivation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
promoter	NULL
by	NULL
human	NULL
herpesvirus	NULL
6	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:970-973	NULL
.	NULL

28	NULL
.	NULL

Hurst	NULL
,	NULL
H.	NULL
C.	NULL
,	NULL
and	NULL
N.	NULL
C.	NULL
Jones	NULL
.	NULL

1987	NULL
.	NULL

Identification	NULL
of	NULL
factors	NULL
that	NULL
interact	NULL
with	NULL
the	NULL
E1	NULL
A-inducible	NULL
adenovirus	NULL
E3	NULL
promoter	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

1:1132-1146	NULL
.	NULL

29	NULL
.	NULL

Kamine	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
G.	NULL
Chinnadurai	NULL
.	NULL

1992	NULL
.	NULL

Synergistic	NULL
activation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
promoter	NULL
by	NULL
the	NULL
viral	NULL
Tat	NULL
protein	NULL
and	NULL
cellular	NULL
transcription	NULL
factor	NULL
SP1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:3932-3936	NULL
.	NULL

30	NULL
.	NULL

Kish-Toth	NULL
,	NULL
E.	NULL
,	NULL
S.	NULL
Paca-uccaralertkun	NULL
,	NULL
I.	NULL
Unk	NULL
,	NULL
and	NULL
I.	NULL
Boros	NULL
.	NULL

1993	NULL
.	NULL

Member	NULL
of	NULL
the	NULL
CREB/ATF	NULL
protein	NULL
family	NULL
but	NULL
not	NULL
CREB	NULL
alpha	NULL
plays	NULL
an	NULL
active	NULL
role	NULL
in	NULL
BLV	NULL
tax	NULL
transactivation	NULL
in	NULL
vivo	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

21:3677-3682	NULL
.	NULL

31	NULL
.	NULL

Lamph	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
V.	NULL
J.	NULL
Dwarki	NULL
,	NULL
R.	NULL
Ofir	NULL
,	NULL
M.	NULL
Montminy	NULL
,	NULL
and	NULL
I.	NULL
M.	NULL
Verma	NULL
.	NULL

1990	NULL
.	NULL

Negative	NULL
and	NULL
positive	NULL
regulation	NULL
by	NULL
transcription	NULL
factor	NULL
cAMP	NULL
response	NULL
element-binding	NULL
protein	NULL
is	NULL
modulated	NULL
by	NULL
phosphorylation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:4320-4324	NULL
.	NULL

32	NULL
.	NULL

Landschulz	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
P.	NULL
F.	NULL
Johnson	NULL
,	NULL
and	NULL
S.	NULL
L.	NULL
McKnight	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
leucine-zipper	NULL
:	NULL
a	NULL
hypothetical	NULL
structure	NULL
common	NULL
to	NULL
a	NULL
new	NULL
class	NULL
of	NULL
DNA	NULL
binding	NULL
proteins	NULL
.	NULL

Science	NULL
240:1759-1764	NULL
.	NULL

33	NULL
.	NULL

Lazdins	NULL
,	NULL
J.	NULL
,	NULL
C.	NULL
Zompetta	NULL
,	NULL
S.	NULL
Grimaldi	NULL
,	NULL
G.	NULL
Barile	NULL
,	NULL
M.	NULL
Venanzoni	NULL
,	NULL
L.	NULL
Frati	NULL
,	NULL
and	NULL
A.	NULL
Faggioni	NULL
.	NULL

1987	NULL
.	NULL

TPA	NULL
induction	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
carly	NULL
antigens	NULL
in	NULL
Raji	NULL
cells	NULL
is	NULL
blocked	NULL
by	NULL
selective	NULL
protein	NULL
kinase-C	NULL
inhibitor	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
40	NULL
:	NULL
846-849	NULL
.	NULL

34	NULL
.	NULL

Lee	NULL
,	NULL
W.	NULL
,	NULL
P.	NULL
Mitchell	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1987	NULL
.	NULL

Purified	NULL
transcription	NULL
factor	NULL
AP-1	NULL
interacts	NULL
with	NULL
TPA-inducible	NULL
enhancer	NULL
elements	NULL
.	NULL

Cell	NULL
49:741-752	NULL
.	NULL

35	NULL
.	NULL

Lieberman	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Berk	NULL
.	NULL

1990	NULL
.	NULL

In	NULL
vitro	NULL
transcriptional	NULL
activation	NULL
,	NULL
dimerization	NULL
,	NULL
and	NULL
DNA-binding	NULL
specificity	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
Zta	NULL
protein	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:2560-2568	NULL
.	NULL

36	NULL
.	NULL

Lieberman	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
J.	NULL
M.	NULL
Hardwick	NULL
,	NULL
J	NULL
.	NULL

Sample	NULL
,	NULL
G.	NULL
S.	NULL
Hayward	NULL
,	NULL
and	NULL
D.	NULL
Hayward	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
Zta	NULL
transactivator	NULL
involved	NULL
in	NULL
induction	NULL
of	NULL
lytic	NULL
cycle	NULL
gene	NULL
expression	NULL
in	NULL
Epstein-Barr	NULL
virus-infected	NULL
lymphocytes	NULL
binds	NULL
both	NULL
AP-1	NULL
and	NULL
ZRE	NULL
sites	NULL
in	NULL
target	NULL
promoter	NULL
and	NULL
enhancer	NULL
regions	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:1143-1155	NULL
.	NULL

37	NULL
.	NULL

Lin	NULL
,	NULL
Y.-S.	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Green	NULL
.	NULL

1988	NULL
.	NULL

Interaction	NULL
of	NULL
a	NULL
common	NULL
cellular	NULL
transcription	NULL
factor	NULL
,	NULL
ATF	NULL
,	NULL
with	NULL
regulatory	NULL
elements	NULL
in	NULL
both	NULL
E1A-	NULL
and	NULL
cyclic	NULL
voL	NULL
.	NULL

70	NULL
,	NULL
1996	NULL
38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

AMP-inducible	NULL
promoters	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:3396-3400	NULL
.	NULL

Lusso	NULL
,	NULL
P.	NULL
,	NULL
P.	NULL
D.	NULL
Markham	NULL
,	NULL
E.	NULL
Tschachler	NULL
,	NULL
F.	NULL
M.	NULL
Veronese	NULL
,	NULL
Z.	NULL
Salahuddin	NULL
,	NULL
D.	NULL
V.	NULL
Ablashi	NULL
,	NULL
S.	NULL
Pahwa	NULL
,	NULL
K.	NULL
Krohn	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1988	NULL
.	NULL

In	NULL
vitro	NULL
cellular	NULL
tropism	NULL
of	NULL
human	NULL
B-lymphotropic	NULL
virus	NULL
(	NULL
buman	NULL
herpesvirus-6	NULL
)	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

167:1659-1670	NULL
.	NULL

Martin	NULL
,	NULL
M.	NULL
E.	NULL
D.	NULL
,	NULL
J.	NULL
Nicholas	NULL
,	NULL
B.	NULL
J.	NULL
Thompson	NULL
,	NULL
C.	NULL
N	NULL
,	NULL
and	NULL
R.	NULL
W.	NULL
Honess	NULL
.	NULL

1991	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
transactivation	NULL
function	NULL
mapping	NULL
to	NULL
the	NULL
putative	NULL
immediate-early	NULL
locus	NULL
of	NULL
human	NULL
herpesvirus	NULL
6	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:5381-5390	NULL
.	NULL

Matthews	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
C.	NULL
R.	NULL
Guthrie	NULL
,	NULL
L.	NULL
M.	NULL
Wailes	NULL
,	NULL
X	NULL
.	NULL

Z.	NULL
Zhao	NULL
,	NULL
A.	NULL
R.	NULL
Means	NULL
,	NULL
and	NULL
G.	NULL
S.	NULL
McKnight	NULL
.	NULL

1994	NULL
.	NULL

Calcium/calmodulin-dependent	NULL
protein	NULL
kinase	NULL
types	NULL
II	NULL
and	NULL
IV	NULL
differentially	NULL
regulate	NULL
CREB-dependent	NULL
gene	NULL
expression	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:6107-6116	NULL
.	NULL

Mellingboff	NULL
,	NULL
L	NULL
,	NULL
M.	NULL
Daibata	NULL
,	NULL
R.	NULL
E.	NULL
Humphreys	NULL
,	NULL
C.	NULL
Mulden	NULL
,	NULL
K.	NULL
Takada	NULL
,	NULL
and	NULL
T.	NULL
Sairenji	NULL
.	NULL

1991	NULL
.	NULL

Early	NULL
events	NULL
in	NULL
Epstein-Barr	NULL
virus	NULL
gene	NULL
expression	NULL
after	NULL
activation	NULL
:	NULL
regulation	NULL
by	NULL
second	NULL
messengers	NULL
of	NULL
B	NULL
cell	NULL
activation	NULL
.	NULL

Virology	NULL
185:922-928	NULL
.	NULL

Meyer	NULL
,	NULL
T.	NULL
E.	NULL
,	NULL
G.	NULL
Waeber	NULL
,	NULL
J.	NULL
Lin	NULL
,	NULL
W.	NULL
Beckmann	NULL
,	NULL
and	NULL
J.	NULL
F.	NULL
Habener	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
promoter	NULL
of	NULL
the	NULL
gene	NULL
encoding	NULL
3',5'-cyclic	NULL
adenosine	NULL
monophosphate	NULL
(	NULL
cAMP	NULL
)	NULL
response	NULL
element	NULL
binding	NULL
protein	NULL
contains	NULL
cAMP	NULL
response	NULL
ele-ment	NULL
:	NULL
evidence	NULL
for	NULL
positive	NULL
autoregulation	NULL
of	NULL
gene	NULL
transcription	NULL
.	NULL

Endocri-nology	NULL
132:770-780	NULL
.	NULL

Montalvo	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Y.	NULL
Shi	NULL
,	NULL
T.	NULL
E.	NULL
Shenk	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Levine	NULL
.	NULL

1991	NULL
.	NULL

Negative	NULL
regulation	NULL
of	NULL
the	NULL
BZLF1	NULL
promoter	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:3647-3655	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
inducible	NULL
transcription	NULL
factor	NULL
activates	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
326:711-713	NULL
.	NULL

EBV	NULL
ZEBRA	NULL
PROMOTER	NULL
ACTIVATION	NULL
BY	NULL
HHV-6	NULL
45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

1791	NULL
Nishizuka	NULL
,	NULL
Y	NULL
.	NULL

1986	NULL
.	NULL

Studies	NULL
and	NULL
perspectives	NULL
of	NULL
protein	NULL
kinase	NULL
C.	NULL
Science	NULL
233:305-312	NULL
.	NULL

Orellana	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
and	NULL
G.	NULL
S.	NULL
McKnight	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
$	NULL
49-kin-cell	NULL
line	NULL
transcribes	NULL
and	NULL
translates	NULL
a	NULL
functional	NULL
mRNA	NULL
coding	NULL
for	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
cAMP-dependent	NULL
kinase	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265:3048-3053	NULL
.	NULL

Sassone-Corsi	NULL
,	NULL
P.	NULL
1988	NULL
.	NULL

Cyclic	NULL
AMP	NULL
induction	NULL
of	NULL
early	NULL
adenovirus	NULL
promoter	NULL
involves	NULL
sequences	NULL
required	NULL
for	NULL
E1A	NULL
transactivation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:7192-7196	NULL
.	NULL

Sassone-Corsi	NULL
,	NULL
P.	NULL
,	NULL
W.	NULL
W.	NULL
Lamph	NULL
,	NULL
M.	NULL
Kamps	NULL
,	NULL
and	NULL
I.	NULL
M.	NULL
Verma	NULL
.	NULL

1988	NULL
.	NULL

Fos-associated	NULL
cellular	NULL
p39	NULL
is	NULL
related	NULL
to	NULL
nuclear	NULL
transcription	NULL
factor	NULL
AP-1	NULL
.	NULL

Cell	NULL
54:553-560	NULL
.	NULL

Shimizu	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
K.	NULL
Takada	NULL
.	NULL

1993	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
BZLF1	NULL
promoter	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
:	NULL
identification	NULL
of	NULL
an	NULL
anti-immunoglobulin	NULL
response	NULL
sequence	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:3240-3245	NULL
.	NULL

Sun	NULL
,	NULL
P.	NULL
,	NULL
H.	NULL
Enslen	NULL
,	NULL
P.	NULL
S.	NULL
Myung	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Maurer	NULL
,	NULL
1994	NULL
.	NULL

Differential	NULL
activation	NULL
of	NULL
CREB	NULL
by	NULL
Ca**/calmodulin-dependent	NULL
protein	NULL
kinases	NULL
type	NULL
II	NULL
and	NULL
type	NULL
IV	NULL
involves	NULL
phosphorylation	NULL
of	NULL
a	NULL
site	NULL
that	NULL
negatively	NULL
regulates	NULL
activity	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

8:2527-2539	NULL
.	NULL

Takada	NULL
,	NULL
K.	NULL
,	NULL
N.	NULL
Shimizu	NULL
,	NULL
S.	NULL
Sakuma	NULL
,	NULL
and	NULL
Y.	NULL
Ono	NULL
.	NULL

1986.	NULL
frans-activation	NULL
of	NULL
the	NULL
latent	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
genome	NULL
after	NULL
transfection	NULL
of	NULL
the	NULL
EBV	NULL
DNA	NULL
fragment	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

57:1016-1022	NULL
.	NULL

Waeber	NULL
,	NULL
G.	NULL
,	NULL
T.	NULL
E.	NULL
Meyer	NULL
,	NULL
M.	NULL
LeSieur	NULL
,	NULL
H.	NULL
L.	NULL
Hermann	NULL
,	NULL
N.	NULL
Gerard	NULL
,	NULL
and	NULL
J.	NULL
F.	NULL
Habener	NULL
.	NULL

1991	NULL
.	NULL

Development	NULL
stage-specific	NULL
expression	NULL
of	NULL
the	NULL
cyclic	NULL
response	NULL
clement	NULL
binding	NULL
protein	NULL
CREB	NULL
during	NULL
spermatogenesis	NULL
involves	NULL
alternative	NULL
exon	NULL
splicing	NULL
.	NULL

Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

5:1418-1430	NULL
.	NULL

Xie	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
T.	NULL
L.	NULL
Rothstein	NULL
.	NULL

1995	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
mediates	NULL
activation	NULL
of	NULL
a	NULL
nuclear	NULL
cAMP	NULL
response	NULL
element-binding	NULL
protein	NULL
(	NULL
CREB	NULL
)	NULL
in	NULL
B	NULL
lymphocytes	NULL
stimulated	NULL
through	NULL
surface	NULL
Ig	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:1717-1723	NULL
.	NULL

